Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,8.899999618530273,9.239999771118164,8.670000076293945,8.739999771118164,62425,0.0,0.0,,,,,,,,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-06-28,8.739999771118164,8.800000190734863,8.520000457763672,8.699999809265137,32138,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-06-29,8.699999809265137,8.699999809265137,8.3100004196167,8.670000076293945,60315,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-06-30,8.680000305175781,8.680000305175781,8.100000381469727,8.369999885559082,89141,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-01,8.300000190734863,8.300000190734863,8.029999732971191,8.170000076293945,32224,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-04,8.220000267028809,8.8100004196167,7.579999923706055,7.679999828338623,155592,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-05,7.679999828338623,7.96999979019165,7.329999923706055,7.550000190734863,39355,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-06,7.550000190734863,7.550000190734863,7.059999942779541,7.199999809265137,86581,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-07,7.199999809265137,7.46999979019165,7.119999885559082,7.239999771118164,47116,0.0,0.0,,,,,,,3.1539321204859903,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-08,7.239999771118164,7.320000171661377,7.150000095367432,7.320000171661377,36581,0.0,0.0,7.963999938964844,,,-8.086385889490272,,,9.314323531911526,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-11,7.320000171661377,8.329999923706055,7.28000020980835,8.050000190734863,83140,0.0,0.0,7.894999980926514,,,1.9632705532971977,,,44.19647883561136,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-12,8.6899995803833,8.6899995803833,6.050000190734863,6.420000076293945,514806,0.0,0.0,7.667000007629395,,,-16.264509326914904,,,22.959912722239153,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-13,6.610000133514404,6.900000095367432,5.900000095367432,5.96999979019165,120300,0.0,0.0,7.396999979019165,,,-19.29160731208673,,,20.089897598463736,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-14,6.0,6.260000228881836,5.920000076293945,6.090000152587891,90718,0.0,0.0,7.1690000057220455,,,-15.050911595381992,,,22.859090184764582,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-15,6.090000152587891,6.400000095367432,5.96999979019165,6.0,77121,0.0,0.0,6.951999998092651,,,-13.693901011994267,,,22.2366938012928,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-18,6.0,6.199999809265137,5.619999885559082,5.809999942779541,129150,0.0,0.0,6.7650000095367435,,,-14.116778498313694,,,20.940442674055106,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-19,5.809999942779541,5.989999771118164,5.590000152587891,5.989999771118164,58727,0.0,0.0,6.608999967575073,,,-9.366019057252746,,,25.378432876537772,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-20,5.989999771118164,5.989999771118164,5.510000228881836,5.699999809265137,98977,0.0,0.0,6.458999967575073,,,-11.751047563403077,,,23.12604178939273,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-21,5.699999809265137,5.800000190734863,5.5,5.800000190734863,62690,0.0,0.0,6.315000009536743,,,-8.155183183280146,,,25.57885100635785,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-22,5.800000190734863,5.800000190734863,5.400000095367432,5.619999885559082,44358,0.0,0.0,6.144999980926514,,,-8.543532904751524,,,24.088945958446104,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-25,5.619999885559082,6.199999809265137,5.5,5.78000020980835,95119,0.0,0.0,5.917999982833862,,,-2.3318650460595447,,,28.098078031831264,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-26,6.0,6.0,5.550000190734863,5.630000114440918,72315,0.0,0.0,5.83899998664856,,,-3.579377850411716,,,26.675695379467697,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-27,5.619999885559082,5.769999980926514,5.5,5.650000095367432,72157,0.0,0.0,5.807000017166137,,,-2.703632191055562,,,27.20482872897638,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-28,5.659999847412109,5.670000076293945,5.5,5.550000190734863,68513,0.0,0.0,5.753000020980835,,,-3.5285908135867174,,,26.187264111108973,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-07-29,5.550000190734863,5.900000095367432,5.489999771118164,5.900000095367432,92621,0.0,0.0,5.743000030517578,,,2.7337639563916936,,,35.30781083960315,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-01,5.900000095367432,7.230000019073486,5.849999904632568,7.099999904632568,326182,0.0,0.0,5.872000026702881,,,20.912804365554607,,,55.575686443222764,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-02,6.960000038146973,7.039999961853027,6.289999961853027,6.800000190734863,208039,0.0,0.0,5.953000068664551,,,14.228122161945848,,,51.25257511075004,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-03,7.0,7.269999980926514,6.5,6.800000190734863,443030,0.0,0.0,6.063000106811524,,,12.155699669134941,,,51.25257511075004,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-04,6.900000095367432,6.949999809265137,6.510000228881836,6.710000038146973,125239,0.0,0.0,6.154000091552734,,,9.03477312841496,,,49.90199222980837,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-05,6.710000038146973,6.849999904632568,6.420000076293945,6.829999923706055,134783,0.0,0.0,6.275000095367432,,,8.84461864388426,,,51.728488206179826,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-08,6.840000152587891,6.849999904632568,6.420000076293945,6.829999923706055,190462,0.0,0.0,6.380000066757202,,,7.053289220066987,,,51.72848820617981,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-09,6.840000152587891,7.099999904632568,6.550000190734863,6.599999904632568,193276,0.0,0.0,6.477000045776367,,,1.8990251348911014,,,47.850544048800884,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-10,6.690000057220459,7.0,6.690000057220459,6.829999923706055,111175,0.0,0.0,6.5950000286102295,,,3.563303928375372,,,51.746261198735056,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-11,7.800000190734863,7.800000190734863,6.840000152587891,7.380000114440918,403757,0.0,0.0,6.778000020980835,,,8.881677362004021,,,59.5315369139998,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-12,7.570000171661377,7.570000171661377,7.179999828338623,7.349999904632568,94053,0.0,0.0,6.923000001907349,,,6.167844902608364,,,58.97262977278171,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-15,7.360000133514404,7.53000020980835,7.010000228881836,7.25,169623,0.0,0.0,6.938000011444092,,,4.496973018755703,,,57.04994635187924,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-16,7.25,7.320000171661377,7.019999980926514,7.239999771118164,74645,0.0,0.0,6.9819999694824215,,,3.6952134454802668,,,56.850334946603915,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-17,7.230000019073486,7.230000019073486,7.03000020980835,7.139999866485596,118207,0.0,0.0,7.0159999370574955,,,1.767387835526488,,,54.786028082609825,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-18,7.090000152587891,7.199999809265137,6.929999828338623,7.0,58129,0.0,0.0,7.0449999332427975,,,-0.6387499456239757,,,51.94238034748408,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-19,7.070000171661377,7.139999866485596,6.909999847412109,7.070000171661377,106571,0.0,0.0,7.06899995803833,6.863249993324279,,0.014149294511019631,2.997850361187177,,53.24901131473105,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-22,7.0,7.099999904632568,6.599999904632568,6.820000171661377,91150,0.0,0.0,7.067999982833863,6.8152500033378605,,-3.508769266762958,3.7085943930481564,,48.207813786388975,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-23,6.800000190734863,6.800000190734863,6.28000020980835,6.639999866485596,73343,0.0,0.0,7.071999979019165,6.763750004768371,,-6.108598894445766,4.557382724575581,,44.911011386843576,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-24,6.639999866485596,6.800000190734863,6.420000076293945,6.800000190734863,117315,0.0,0.0,7.069000005722046,6.7170000076293945,,-3.8053446706668415,5.240434683531904,,48.295815047568084,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-25,6.949999809265137,6.949999809265137,6.760000228881836,6.949999809265137,41395,0.0,0.0,7.025999975204468,6.681500005722046,,-1.0816989212573902,5.156027376897283,,51.315838741756984,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-26,6.96999979019165,7.199999809265137,6.71999979019165,6.71999979019165,60402,0.0,0.0,6.962999963760376,6.645249998569488,,-3.489877564748592,4.781610402306756,,46.801758962616304,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-29,6.869999885559082,7.050000190734863,6.300000190734863,6.769999980926514,176219,0.0,0.0,6.914999961853027,6.622500002384186,,-2.096890552804251,4.416760428290491,,47.87523022059298,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-30,6.539999961853027,7.090000152587891,6.400000095367432,6.53000020980835,212524,0.0,0.0,6.844000005722046,6.597000002861023,,-4.587957271349673,3.744126159677171,,43.35315571596278,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-08-31,6.519999980926514,6.840000152587891,5.599999904632568,6.389999866485596,404266,0.0,0.0,6.769000005722046,6.576750004291535,,-5.5990565654612166,2.9231763607414325,,40.924778591978,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-01,6.400000095367432,6.599999904632568,6.110000133514404,6.340000152587891,82244,0.0,0.0,6.703000020980835,6.554250013828278,,-5.41548362310504,2.269519881584039,,40.06170476743143,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-02,6.599999904632568,6.679999828338623,6.340000152587891,6.480000019073486,104766,0.0,0.0,6.644000005722046,6.53325001001358,,-2.468392331536984,1.6951746150647602,,43.64543642693687,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-05,6.519999980926514,6.519999980926514,6.110000133514404,6.329999923706055,72750,0.0,0.0,6.594999980926514,6.49025000333786,,-4.018196481984371,1.6139590545014733,,40.828705850901926,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-06,6.329999923706055,6.329999923706055,5.929999828338623,6.079999923706055,106931,0.0,0.0,6.53899998664856,6.481749999523163,,-7.019422906861891,0.8832489239728274,,36.59027328692739,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-07,6.079999923706055,6.150000095367432,5.809999942779541,6.0,50765,0.0,0.0,6.458999967575073,6.482500004768371,,-7.106362747783029,-0.3625150354957571,,35.32648496606622,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-08,6.0,6.179999828338623,6.0,6.179999828338623,113240,0.0,0.0,6.381999969482422,6.48474999666214,,-3.1651542166989537,-1.5844871002368068,,40.32104349410411,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-09,6.269999980926514,6.369999885559082,5.800000190734863,6.199999809265137,226556,0.0,0.0,6.32999997138977,6.489749991893769,,-2.0537150507457533,-2.461574339589957,,40.86747937249867,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-12,6.199999809265137,6.199999809265137,5.860000133514404,6.0,72422,0.0,0.0,6.252999973297119,6.49449999332428,,-4.046057482448956,-3.718531376940479,,37.19940092364112,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-13,5.989999771118164,5.989999771118164,5.75,5.849999904632568,61718,0.0,0.0,6.184999942779541,6.49099999666214,,-5.416330497109488,-4.714220521336512,,34.6849213373322,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-14,5.849999904632568,5.940000057220459,5.599999904632568,5.920000076293945,73634,0.0,0.0,6.137999963760376,6.49650000333786,,-3.5516436747072846,-5.518356644243651,,36.830822158977014,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-15,5.900000095367432,5.909999847412109,5.699999809265137,5.860000133514404,105136,0.0,0.0,6.089999961853027,6.498000001907348,,-3.776680291942727,-6.278855646884603,,35.746723402523386,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-16,5.860000133514404,5.860000133514404,5.599999904632568,5.849999904632568,105896,0.0,0.0,6.0269999504089355,6.503750002384185,,-2.9367852535714327,-7.330387112058117,,35.55885704583089,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-19,5.849999904632568,5.849999904632568,5.25,5.5,133376,0.0,0.0,5.94399995803833,6.496749997138977,,-7.469716708828199,-8.508100809544242,,29.67970126537915,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-20,5.5,5.5,5.150000095367432,5.239999771118164,91240,0.0,0.0,5.859999942779541,6.486999988555908,,-10.58020781084335,-9.66548553849999,,26.212591284298256,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-21,5.239999771118164,5.239999771118164,5.010000228881836,5.179999828338623,61923,0.0,0.0,5.777999925613403,6.475249981880188,,-10.349603755166115,-10.767924917461292,,25.473069183828173,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-22,5.150000095367432,5.179999828338623,5.0,5.179999828338623,82929,0.0,0.0,5.6779999256134035,6.465999972820282,,-8.770695734395959,-12.186824165159651,,25.473069183828173,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-23,5.170000076293945,5.179999828338623,5.03000020980835,5.090000152587891,99641,0.0,0.0,5.5669999599456785,6.445749974250793,,-8.568345801864211,-13.63301427786538,,24.281351110807705,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-26,5.090000152587891,5.090000152587891,4.724999904632568,4.965000152587891,200295,0.0,0.0,5.463499975204468,6.392374980449676,,-9.124184586418366,-14.530984306866584,,22.69337114790659,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-27,5.0,5.090000152587891,4.650000095367432,4.699999809265137,81231,0.0,0.0,5.348499965667725,6.339874970912933,,-12.124897832389294,-15.637138110666113,,19.745187468633205,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-28,4.75,4.889999866485596,4.690000057220459,4.690000057220459,150044,0.0,0.0,5.225499963760376,6.287124967575073,,-10.247821457347404,-16.88569909600768,,19.641492547351532,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-29,4.690000057220459,6.099999904632568,4.59499979019165,6.059999942779541,434518,0.0,0.0,5.245499944686889,6.270874965190887,,15.527595208873274,-16.35138678726287,,54.723528152921745,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-09-30,6.090000152587891,6.230000019073486,1.6019999980926514,2.4200000762939453,4204222,0.0,0.0,4.902499961853027,6.1606249690055845,,-50.63742794239118,-20.422035320803456,,24.33063985991427,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-03,2.505000114440918,2.799999952316284,2.5,2.75,1160530,0.0,0.0,4.627499961853028,6.058624970912933,,-40.572662935284065,-23.621283970053337,,28.222722227751447,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-04,2.75,2.755000114440918,1.7999999523162842,2.0799999237060547,1227186,0.0,0.0,4.311499977111817,5.945624971389771,,-51.756930656430086,-27.48449493772868,,25.369594687096736,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-05,2.1050000190734863,2.255000114440918,2.009999990463257,2.055000066757202,323568,0.0,0.0,3.999000000953674,5.826249974966049,,-48.61215138116705,-31.362368279143787,,25.26695329892202,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-06,2.055000066757202,2.059999942779541,1.934000015258789,2.049999952316284,143810,0.0,0.0,3.6860000133514403,5.6929999709129335,,-44.38415776205187,-35.25381991596338,,25.244953907118344,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-07,2.055000066757202,2.055000066757202,1.9240000247955322,2.0399999618530273,172648,0.0,0.0,3.3809999942779543,5.560249972343445,,-39.66282267655876,-39.19338139301344,,25.197701596511536,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-10,2.0399999618530273,2.0399999618530273,1.899999976158142,1.99399995803833,187067,0.0,0.0,3.083899974822998,5.428849971294403,,-35.34161372556265,-43.19423098576248,,24.96620534059595,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-11,1.99399995803833,2.259999990463257,1.9500000476837158,2.1500000953674316,249909,0.0,0.0,2.8289000034332275,5.301599979400635,,-23.99872414160504,-46.640636516807795,,27.402102139609454,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-12,2.259999990463257,2.380000114440918,2.1549999713897705,2.380000114440918,328529,0.0,0.0,2.5979000091552735,5.182599985599518,,-8.387539703085313,-49.87265047709927,,30.96075466403859,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-13,2.4049999713897705,2.4100000858306885,1.9980000257492065,2.244999885559082,348361,0.0,0.0,2.2164000034332276,5.063724982738495,,1.2903754774207217,-56.22985033767406,,30.030264030623982,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-14,2.244999885559082,2.25,2.0250000953674316,2.109999895095825,219597,0.0,0.0,2.1853999853134156,4.939724975824356,,-3.4501734567723554,-55.758670857000304,,29.08878643978612,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-17,2.109999895095825,2.109999895095825,1.7979999780654907,2.0450000762939453,222354,0.0,0.0,2.11489999294281,4.8203499734401705,,-3.3051168793849888,-56.12559244461962,,28.623482847964866,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-18,2.1500000953674316,2.1500000953674316,1.9500000476837158,2.0,81615,0.0,0.0,2.1069000005722045,4.704349976778031,,-5.073805142302528,-55.21379125761382,,28.28614094512048,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-19,2.0199999809265137,2.075000047683716,2.0,2.0450000762939453,34921,0.0,0.0,2.105900001525879,4.585474973917007,,-2.891871655245135,-54.07455032456592,,29.184930839221877,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-20,2.0450000762939453,2.0450000762939453,1.7999999523162842,1.9320000410079956,129117,0.0,0.0,2.0941000103950502,4.460024979710579,,-7.740794068210458,-53.04734794263549,,28.228203169978826,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-21,1.940000057220459,1.9620000123977661,1.75,1.9559999704360962,66164,0.0,0.0,2.085700011253357,4.34092498421669,,-6.218537666848856,-51.95263638886133,,28.762343485800557,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-24,1.9500000476837158,1.9500000476837158,1.840000033378601,1.940000057220459,88454,0.0,0.0,2.0803000211715696,4.2201749861240385,,-6.74421778220708,-50.705834994719204,,28.609479968131808,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-25,1.940000057220459,1.940000057220459,1.7519999742507935,1.9359999895095825,112601,0.0,0.0,2.058900010585785,4.10532498061657,,-5.969207851003694,-49.8480626915786,,28.56860071530724,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-26,1.9359999895095825,2.0899999141693115,1.8420000076293945,1.9800000190734863,149634,0.0,0.0,2.0189000010490417,3.995074984431267,,-1.9267909235396747,-49.46527890173132,,29.757548964712043,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-27,1.9800000190734863,2.005000114440918,1.8519999980926514,1.9980000257492065,124137,0.0,0.0,1.994200015068054,3.8865249812602998,,0.1905531367184727,-48.68938126775178,,30.268883112581477,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-28,2.0,2.0,1.8619999885559082,1.9479999542236328,96526,0.0,0.0,1.978000020980835,3.7732249796390533,,-1.516686877603067,-47.57799941285106,,29.62378128141785,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-10-31,1.9479999542236328,2.049999952316284,1.9479999542236328,2.049999952316284,97004,0.0,0.0,1.9785000085830688,3.666224980354309,,3.6138460158219075,-46.034408166847854,,32.77152495670525,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-01,2.049999952316284,2.140000104904175,1.9700000286102295,2.0899999141693115,69332,0.0,0.0,1.9875,3.5664749801158906,,5.157228385877307,-44.27270593286435,,34.0178856842234,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-02,2.1500000953674316,2.5999999046325684,2.1500000953674316,2.1500000953674316,192412,0.0,0.0,1.9980000019073487,3.4702249825000764,,7.607612278026989,-42.424482217060266,,35.93646201975173,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-03,2.2850000858306885,2.319999933242798,2.1549999713897705,2.174999952316284,156623,0.0,0.0,2.0222999930381773,3.3700999855995177,,7.550806497739239,-39.99287849976285,,36.761556482829,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-04,2.240000009536743,2.240000009536743,2.075000047683716,2.194999933242798,58244,0.0,0.0,2.046199989318848,3.2699749886989595,,7.272013718145091,-37.4245981577682,,37.455554518187036,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-07,2.200000047683716,2.240000009536743,2.1449999809265137,2.200000047683716,153708,0.0,0.0,2.072199988365173,3.1749749898910524,,6.1673612603081,-34.73334451569083,,37.63980963089573,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-08,2.240000009536743,2.325000047683716,2.0999999046325684,2.2149999141693115,115355,0.0,0.0,2.1000999808311462,3.084099990129471,,5.471164915333788,-31.90558063770871,,38.2277273011826,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-09,2.2149999141693115,2.444999933242798,2.119999885559082,2.3450000286102295,192855,0.0,0.0,2.1365999817848205,2.994724988937378,,9.753816746329882,-28.654551263388196,,43.22366972091559,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-10,2.3450000286102295,2.3550000190734863,2.1500000953674316,2.3550000190734863,79681,0.0,0.0,2.1722999811172485,2.907099986076355,,8.410442367277113,-25.27604858719871,,43.6015303978269,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-11,2.3550000190734863,2.5,2.200000047683716,2.3350000381469727,193312,0.0,0.0,2.2109999895095824,2.819224989414215,,5.6083242526335075,-21.57419156642092,,42.98536168277243,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-14,2.200000047683716,2.3499999046325684,2.200000047683716,2.3350000381469727,197934,0.0,0.0,2.2394999980926515,2.7400999903678893,,4.2643465119739705,-18.269406008356164,,42.98536168277243,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-15,2.3399999141693115,2.3499999046325684,2.2049999237060547,2.319999933242798,74638,0.0,0.0,2.2625,2.6670999944210054,,2.5414335134938195,-15.170034691887842,,42.46339034201532,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-16,2.319999933242798,2.319999933242798,2.109999895095825,2.2300000190734863,136848,0.0,0.0,2.2704999923706053,2.593349999189377,,-1.7837469030261202,-12.44914905121512,,39.37403094963317,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-17,2.1449999809265137,2.2049999237060547,2.0,2.130000114440918,215657,0.0,0.0,2.266000008583069,2.517100006341934,,-6.001760530759741,-9.975765648015923,,36.22081202675753,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-18,2.190000057220459,2.305000066757202,2.1600000858306885,2.265000104904175,82095,0.0,0.0,2.2730000257492065,2.4464750051498414,,-0.35195427868043183,-7.090813477982374,,42.872176679146605,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-21,2.2750000953674316,2.2750000953674316,2.0250000953674316,2.184999942779541,172574,0.0,0.0,2.271500015258789,2.3769749999046326,,-3.80805951565856,-4.437361968471498,,40.19691476894944,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-22,2.180000066757202,2.180000066757202,1.909999966621399,1.9819999933242798,169985,0.0,0.0,2.248200023174286,2.309025004506111,,-11.840584783650701,-2.6342279192786613,,34.34101487261465,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-23,2.0199999809265137,2.190000057220459,1.8539999723434448,2.130000114440918,389049,0.0,0.0,2.2267000317573546,2.245025005936623,,-4.342745584824878,-0.8162481099680662,,41.080278323811115,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-24,2.25,2.25,1.8020000457763672,2.109999895095825,390839,0.0,0.0,2.2022000193595885,2.14627500474453,,-4.186727974445102,2.6056779532646823,,40.47567608446461,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-25,2.109999895095825,2.25,2.0250000953674316,2.2249999046325684,107833,0.0,0.0,2.191200006008148,2.1414000004529954,,1.5425291407330646,2.3255816542737393,,45.447322628491044,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-28,2.25,2.5999999046325684,2.2149999141693115,2.319999933242798,199894,0.0,0.0,2.1896999955177305,2.1306499987840652,,5.950584006566586,2.77145456866986,,49.22047991148406,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-29,2.319999933242798,2.444999933242798,2.234999895095825,2.4000000953674316,40967,0.0,0.0,2.197700011730194,2.1386500030755995,,9.205081792667961,2.7610880026967672,,52.2176290168829,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-11-30,2.4000000953674316,2.9600000381469727,2.4000000953674316,2.9600000381469727,199968,0.0,0.0,2.270700013637543,2.1612750023603438,,30.35627869685909,5.06298417173637,,66.9312446143727,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-01,3.005000114440918,3.9749999046325684,2.7699999809265137,3.180000066757202,1031471,0.0,0.0,2.3757000088691713,2.189525005221367,,33.855287068457606,8.502985953749427,,70.74281299436268,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-02,3.1500000953674316,3.1500000953674316,2.5250000953674316,3.0850000381469727,142583,0.0,0.0,2.4577000021934508,2.2156500071287155,,25.523865215187712,10.92455912648453,,67.14384680056112,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-05,3.0850000381469727,3.115000009536743,2.7850000858306885,3.0950000286102295,103479,0.0,0.0,2.54870001077652,2.243175008893013,,21.43445739097662,13.620203536160153,,67.33224436051236,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-06,3.0950000286102295,3.244999885559082,2.944999933242798,3.005000114440918,97680,0.0,0.0,2.6510000228881836,2.26455000936985,,13.353454865951381,17.06520111807422,,63.78721843233175,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-07,3.299999952316284,3.299999952316284,2.825000047683716,3.184999942779541,40882,0.0,0.0,2.756500005722046,2.2846750050783156,,15.545072960928675,20.651733817500087,,67.4754814250542,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-08,3.184999942779541,3.299999952316284,2.994999885559082,3.134999990463257,84176,0.0,0.0,2.859000015258789,2.30692500770092,,9.653724159895997,23.931207374099536,,65.48043175381189,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-09,3.134999990463257,3.134999990463257,2.9600000381469727,3.0999999046325684,38285,0.0,0.0,2.9465000152587892,2.3316750079393387,4.7115499923626585,5.209566895600281,26.36838346793508,-50.511508702678654,64.05275548373987,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-12,3.0999999046325684,3.1600000858306885,2.930000066757202,3.049999952316284,39731,0.0,0.0,3.0195000171661377,2.356800004839897,4.664133327205976,1.0100988566567817,28.11863590314526,-49.46971195929072,61.973956046227954,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-13,3.0199999809265137,3.1500000953674316,2.5850000381469727,2.990000009536743,261770,0.0,0.0,3.078500008583069,2.381550005078316,4.616549995541573,-2.8747766379594513,29.264554681556405,-48.41277561429434,59.479322734004135,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-14,2.990000009536743,2.990000009536743,2.825000047683716,2.934999942779541,80634,0.0,0.0,3.0759999990463256,2.4038000017404557,4.568758327762286,-4.583876993189202,27.964056777567514,-47.38614237628534,57.20612561566893,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-15,2.859999895095825,2.994999885559082,2.640000104904175,2.7149999141693115,59276,0.0,0.0,3.0294999837875367,2.4233749985694883,4.521633328000704,-10.381253385089357,25.01160511996048,-46.404875787639035,49.11946984135091,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-16,2.694999933242798,2.694999933242798,2.5,2.6050000190734863,138532,0.0,0.0,2.981499981880188,2.439599999785423,4.475258327523867,-12.627870705847668,22.212657080768494,-45.486945752799954,45.64510925703471,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-19,2.6050000190734863,2.700000047683716,2.4049999713897705,2.6500000953674316,45834,0.0,0.0,2.9369999885559084,2.4573500007390976,4.433341663082441,-9.77187246533125,19.51899353663688,-44.571156759649874,47.28773475911183,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-20,2.6649999618530273,2.7100000381469727,2.509999990463257,2.6050000190734863,70648,0.0,0.0,2.896999979019165,2.4740750014781954,4.392133328318596,-10.079391165357924,17.094266636552366,-43.6703119751302,45.797261705169284,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-21,2.505000114440918,2.9000000953674316,2.505000114440918,2.9000000953674316,82861,0.0,0.0,2.868499994277954,2.497075003385544,4.356299997369448,1.0981384400318468,14.874402666673234,-42.67899352906359,55.6631095051395,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-22,2.869999885559082,2.869999885559082,2.5899999141693115,2.799999952316284,84915,0.0,0.0,2.834999990463257,2.517125001549721,4.3192999988794325,-1.234569250959807,12.628494362331221,-41.72377463471523,52.194906694867434,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-23,2.75,2.884999990463257,2.6500000953674316,2.799999952316284,45497,0.0,0.0,2.8049999952316282,2.538425001502037,4.28163333038489,-0.1782546496914048,10.501590299963702,-40.71362945799356,52.194906694867434,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-27,2.619999885559082,2.634999990463257,2.5299999713897705,2.5899999141693115,127257,0.0,0.0,2.758999991416931,2.551925000548363,4.236133328080177,-6.12541057533047,8.114462251989043,-39.75815200073271,45.317962268485395,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-28,2.5999999046325684,2.619999885559082,2.125,2.5,528085,0.0,0.0,2.709999990463257,2.56217500269413,4.203466660777727,-7.749077166135299,5.769511747389961,-39.04614430271048,42.72015112971221,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-29,2.25,2.494999885559082,2.25,2.3499999046325684,56381,0.0,0.0,2.6514999866485596,2.5671749979257585,4.173299995064736,-11.370925270004658,3.284738624789289,-38.48573069365609,38.73474964934045,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2022-12-30,2.3450000286102295,2.944999933242798,2.2750000953674316,2.799999952316284,160689,0.0,0.0,2.6599999904632567,2.5827999979257585,4.145883326729138,5.263156479509818,2.989003894978216,-37.702057815422464,52.92362614489011,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-02,2.799999952316284,2.799999952316284,2.575000047683716,2.75,43167,0.0,0.0,2.674499988555908,2.5966749995946885,4.118799993395806,2.8229580021369864,2.9971016385711455,-36.95554521321097,51.49652922421629,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-03,2.75,2.75,2.5450000762939453,2.6549999713897705,142170,0.0,0.0,2.674999976158142,2.6080499976873397,4.0925083269675575,-0.7476637363225578,2.5670511888257312,-36.27257932496775,48.80377849153331,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-04,2.6549999713897705,2.6549999713897705,2.424999952316284,2.5999999046325684,80717,0.0,0.0,2.6744999647140504,2.6176749974489213,4.064258328080177,-2.7855696789828652,2.1708182765434354,-35.5927998138488,47.262919481276676,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-05,2.5999999046325684,2.944999933242798,2.549999952316284,2.7899999618530273,44019,0.0,0.0,2.66349995136261,2.6287999957799912,4.0400083293517435,4.749390381092435,1.3199922260469572,-34.93082732822469,52.80623134830504,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-09,2.819999933242798,2.884999990463257,2.634999990463257,2.884999990463257,90363,0.0,0.0,2.671999955177307,2.6420499950647356,4.015716661016146,7.97155834053207,1.1335879399904245,-34.207260668729916,55.33426252474256,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-10,2.890000104904175,3.484999895095825,2.890000104904175,3.265000104904175,109494,0.0,0.0,2.7184999704360964,2.6652999967336655,3.996091662844022,20.103003141854366,1.9960219775495311,-33.30233083700666,63.708532703547895,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-11,3.4000000953674316,3.680000066757202,2.9149999618530273,2.990000009536743,204706,0.0,0.0,2.7584999799728394,2.6816749960184096,3.972841661175092,8.392243293261984,2.864813374793547,-32.49982695697919,55.58632286395362,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-12,2.994999885559082,2.994999885559082,2.8550000190734863,2.9600000381469727,81632,0.0,0.0,2.8044999837875366,2.697674998641014,3.950591660539309,5.544662337613207,3.959890839346362,-31.71465870322966,54.766045615556955,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-13,2.9549999237060547,3.075000047683716,2.805000066757202,2.9000000953674316,60168,0.0,0.0,2.859500002861023,2.7144250005483626,3.9276749938726425,1.4163347601289333,5.344594243103155,-30.889775636146243,53.078987553010045,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-16,2.9000000953674316,3.2950000762939453,2.815000057220459,2.9000000953674316,67634,0.0,0.0,2.869500017166138,2.7336750000715258,3.9055916597445806,1.062905663663844,4.968586868997163,-30.00612357282882,53.078987553010045,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-17,2.9000000953674316,3.2249999046325684,2.8499999046325684,2.930000066757202,41997,0.0,0.0,2.887500023841858,2.750299999117851,3.880841659506162,1.4718629459541013,4.988547604552712,-29.131352412151042,53.90243521413224,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-18,3.049999952316284,3.140000104904175,2.7699999809265137,2.8949999809265137,48752,0.0,0.0,2.911500024795532,2.7680500000715256,3.845799993475278,-0.5667196884251148,5.182349477802055,-28.024078091222776,52.7395469892408,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-19,2.8949999809265137,3.180000066757202,2.815000057220459,3.0,361027,0.0,0.0,2.9515000343322755,2.7935000002384185,3.8141333252191543,1.643231072456917,5.655988332929017,-26.75924614989938,55.81897679058724,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-20,3.0,3.0,2.759999990463257,2.8399999141693115,53815,0.0,0.0,2.956500029563904,2.8112499952316283,3.7811333229144415,-3.9404740141936214,5.166742003686795,-25.650598507202105,50.42696560023696,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-23,2.8399999141693115,2.8949999809265137,2.5999999046325684,2.700000047683716,45219,0.0,0.0,2.93800003528595,2.8259999990463256,3.7477166563272477,-8.100748289442073,3.96320015135953,-24.594085994329195,46.21980481322478,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-24,2.7950000762939453,3.194999933242798,2.575000047683716,2.994999885559082,117703,0.0,0.0,2.9110000133514404,2.8452499985694883,3.715758322676023,2.8856019176355954,2.3108695128726593,-23.427474246484632,54.780861911365434,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-25,3.0899999141693115,3.0999999046325684,2.8399999141693115,2.924999952316284,53144,0.0,0.0,2.9045000076293945,2.860374999046326,3.6832166562477746,0.70579943649652,1.542630200507987,-22.34030017771768,52.63956048693846,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-26,2.875,3.109999895095825,2.7799999713897705,2.865000009536743,61584,0.0,0.0,2.8950000047683715,2.8719999969005583,3.6520916571219764,-1.036269263634375,0.8008359294092842,-21.36013368394395,50.80638055039727,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-27,2.865000009536743,2.869999885559082,2.755000114440918,2.8299999237060547,11287,0.0,0.0,2.887999987602234,2.8687499940395353,3.6187583237886427,-2.008312470400456,0.6710237421418654,-20.72557111147145,49.71866519879446,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-30,2.825000047683716,3.484999895095825,2.7049999237060547,2.994999885559082,50777,0.0,0.0,2.8974999666213987,2.8641249895095826,3.5822166552146277,3.3649670426527076,1.1652765586019644,-20.046014376593334,54.64804654475697,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-01-31,3.0950000286102295,3.0950000286102295,2.7200000286102295,2.765000104904175,157863,0.0,0.0,2.880999970436096,2.8561249911785125,3.544008323550224,-4.026375103168166,0.8709345471368695,-19.409754988459564,47.637345701469535,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-01,2.765000104904175,3.0350000858306885,2.734999895095825,3.0350000858306885,42795,0.0,0.0,2.8949999809265137,2.854624992609024,3.50888332426548,4.835927662402584,1.414371009222765,-18.64577049718269,54.94460603127384,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-02,3.0350000858306885,3.0350000858306885,2.7799999713897705,2.944999933242798,97519,0.0,0.0,2.8894999742507936,2.8531249880790712,3.473091658949852,1.9207461320844819,1.2749173738866824,-17.850570377927728,52.32344643619057,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-03,2.944999933242798,3.009999990463257,2.7899999618530273,2.869999885559082,74985,0.0,0.0,2.8924999713897703,2.8452499866485597,3.437508325775464,-0.7778767866288897,1.6606619791910364,-17.229291771774765,50.17531198760229,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-06,2.865000009536743,2.984999895095825,2.7699999809265137,2.944999933242798,51363,0.0,0.0,2.9169999599456786,2.840499985218048,3.403716658552488,0.959889396009476,2.6931869433457596,-16.547108053757956,52.2849371693416,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-07,2.944999933242798,2.944999933242798,2.759999990463257,2.8350000381469727,18100,0.0,0.0,2.900999975204468,2.833874988555908,3.368424990773201,-2.275075409224831,2.368664352507858,-15.869434637301815,49.007469572649185,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-08,2.8350000381469727,2.8399999141693115,2.700000047683716,2.819999933242798,34645,0.0,0.0,2.890499973297119,2.828124988079071,3.3350916554530463,-2.4390257984989225,2.2055243484982867,-15.20098155458663,48.56044521814,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-09,2.7899999618530273,2.799999952316284,2.549999952316284,2.684999942779541,120439,0.0,0.0,2.872499966621399,2.820499986410141,3.3021333227554956,-6.5274160494558044,1.8436440511188252,-14.585520609551017,44.61601891454836,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-10,2.674999952316284,2.674999952316284,2.484999895095825,2.630000114440918,99481,0.0,0.0,2.852499985694885,2.8128749907016752,3.267383322119713,-7.800170810509749,1.408700888741786,-13.910468610801857,43.080708134367626,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-13,2.630000114440918,2.9000000953674316,2.5450000762939453,2.690000057220459,137094,0.0,0.0,2.822000002861023,2.812249994277954,3.231883324186007,-4.677531733052402,0.3466977901291512,-12.984173245602648,45.29241327219432,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-14,2.559999942779541,2.799999952316284,2.559999942779541,2.744999885559082,54911,0.0,0.0,2.8199999809265135,2.815749990940094,3.198758324980736,-2.6595778678973647,0.15093634023242009,-11.97365649819602,47.31339834866546,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-15,2.744999885559082,2.8350000381469727,2.5850000381469727,2.6449999809265137,112858,0.0,0.0,2.7809999704360964,2.815624988079071,3.1643833249807356,-4.890326895194327,-1.229745359896003,-11.02136818091682,44.12191325246178,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-16,2.569999933242798,2.799999952316284,2.4000000953674316,2.684999942779541,87464,0.0,0.0,2.7549999713897706,2.8176249861717224,3.132341656088829,-2.5408359106050296,-2.2226171009024083,-10.047328946551593,45.69972569270377,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-17,2.684999942779541,2.684999942779541,2.4000000953674316,2.609999895095825,62398,0.0,0.0,2.728999972343445,2.8103749811649323,3.1008416563272476,-4.360574512774068,-2.8955213936524817,-9.367349492664996,43.23463828089192,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-20,2.549999952316284,2.549999952316284,2.1050000190734863,2.3499999046325684,209517,0.0,0.0,2.669499969482422,2.7991249799728393,3.067591654260953,-11.968535999339236,-4.6309118534491125,-8.751708328427862,35.98749532761667,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-21,2.3450000286102295,2.3450000286102295,2.119999885559082,2.119999885559082,33717,0.0,0.0,2.5979999542236327,2.7821249783039095,3.031258319815,-18.398771250455727,-6.6181435239665785,-8.218809326890206,31.03203033236973,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-22,2.200000047683716,2.4600000381469727,2.0899999141693115,2.2699999809265137,82636,0.0,0.0,2.5429999589920045,2.7741249799728394,2.997424986958504,-10.735351257091748,-8.331456680913409,-7.449727948396391,37.11388327943263,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-23,2.265000104904175,2.450000047683716,2.119999885559082,2.1600000858306885,86159,0.0,0.0,2.490499973297119,2.7656249821186067,2.9647583216428757,-13.270423248745875,-9.948022982158923,-6.716680346947208,34.6974674592352,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-24,2.1549999713897705,2.3450000286102295,2.119999885559082,2.200000047683716,42780,0.0,0.0,2.447499966621399,2.7618749856948854,2.9330916553735733,-10.112356376426815,-11.382666511040142,-5.837412866557041,36.32108202076382,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-27,2.2049999237060547,2.2899999618530273,2.200000047683716,2.259999990463257,43152,0.0,0.0,2.404499959945679,2.7483749866485594,2.900424990057945,-6.0095642291333835,-12.511939905340599,-5.242335310534888,38.77988100613705,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-02-28,2.259999990463257,2.259999990463257,2.0899999141693115,2.0899999141693115,87838,0.0,0.0,2.3389999628067017,2.7318749845027925,2.8661749909321466,-10.645577280753807,-14.381149354372633,-4.685687609941658,34.69249336662058,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-01,2.0899999141693115,2.2750000953674316,2.0899999141693115,2.234999895095825,85336,0.0,0.0,2.297999954223633,2.7213749825954436,2.8347999900579453,-2.741516987936231,-15.557394004115793,-4.001164380566515,40.45713839987699,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-02,2.1500000953674316,2.244999885559082,2.059999942779541,2.1549999713897705,99131,0.0,0.0,2.244999957084656,2.7102499842643737,2.804008323947589,-4.008908125404105,-17.166314173266112,-3.3437254405585572,38.44104360903154,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-03,2.1500000953674316,2.1549999713897705,2.0999999046325684,2.1449999809265137,95653,0.0,0.0,2.1984999656677244,2.6941249847412108,2.7725499898195265,-2.4334767148819054,-18.396511738711872,-2.828623662919804,38.18488909339185,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-06,2.140000104904175,2.244999885559082,2.0299999713897705,2.194999933242798,74600,0.0,0.0,2.1829999685287476,2.6768749833106993,2.74200832148393,0.5497006361451199,-18.449685467609626,-2.3753880563710887,40.32603579368281,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-07,2.125,2.2950000762939453,2.125,2.265000104904175,73890,0.0,0.0,2.197499990463257,2.6518749833106994,2.71213332315286,3.0716775760571546,-17.134103066962226,-2.221805960929323,43.28774804720813,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-08,2.265000104904175,2.299999952316284,2.174999952316284,2.2750000953674316,21708,0.0,0.0,2.1980000019073485,2.633999985456467,2.6852583239475885,3.5031889623869503,-16.552770917102357,-1.9088792327349315,43.717498682189515,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-09,2.2750000953674316,2.4549999237060547,2.2750000953674316,2.365000009536743,25724,0.0,0.0,2.218499994277954,2.619124984741211,2.661299992601077,6.603561669445472,-15.296138702706527,-1.5847521127689674,47.568379747959646,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-10,2.2750000953674316,2.5999999046325684,2.2300000190734863,2.450000047683716,80969,0.0,0.0,2.243499994277954,2.607874983549118,2.6385499944289523,9.204370578669046,-13.972103401033337,-1.1625707659359021,50.97971392705986,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-13,2.450000047683716,2.630000114440918,2.255000114440918,2.4749999046325684,62946,0.0,0.0,2.2649999856948853,2.5972499787807464,2.6160083283980686,9.271519658454068,-12.792376390424792,-0.7170600113803562,51.96952197883406,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-14,2.4749999046325684,2.4749999046325684,2.194999933242798,2.3499999046325684,204409,0.0,0.0,2.290999984741211,2.582749974727631,2.593174992998441,2.5752911516506143,-11.296098841978958,-0.4020175383056609,46.87319937672202,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-15,2.3499999046325684,2.3499999046325684,2.2149999141693115,2.3450000286102295,21948,0.0,0.0,2.3019999980926515,2.5689999759197235,2.5713416586319604,1.8679422481844534,-10.393148319570681,-0.09106851687234536,46.676031563307205,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-16,2.3350000381469727,2.3350000381469727,2.0450000762939453,2.174999952316284,56229,0.0,0.0,2.303999996185303,2.5483749747276305,2.550299993157387,-5.598960246640713,-9.589443506776172,-0.07548203877666494,40.446356534312244,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-17,2.1700000762939453,2.1700000762939453,2.109999895095825,2.1500000953674316,22833,0.0,0.0,2.3045000076293944,2.5311249792575836,2.5291333268086116,-6.704270416596553,-8.953527521768665,0.07874841661610638,39.60913589490553,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-20,2.1500000953674316,2.3499999046325684,2.055000066757202,2.244999885559082,44609,0.0,0.0,2.309500002861023,2.519749975204468,2.497341659665108,-2.7928173726797003,-8.344080738660749,0.8972867389864828,44.32529302437422,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-21,2.244999885559082,2.2899999618530273,2.075000047683716,2.200000047683716,89071,0.0,0.0,2.302999997138977,2.4998749792575836,2.495508326093356,-4.472425079601313,-7.875393119742127,0.1749805087231887,42.62714232711616,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-22,2.2850000858306885,2.299999952316284,2.1050000190734863,2.240000009536743,50791,0.0,0.0,2.299499988555908,2.4827499806880953,2.4912583261728285,-2.587518126344118,-7.380928146514345,-0.34152803004592824,44.65679727645564,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-23,2.2850000858306885,2.2850000858306885,2.119999885559082,2.2049999237060547,14207,0.0,0.0,2.2834999799728393,2.466249978542328,2.4922999928394955,-3.4377077711959645,-7.410035485433748,-1.0452198520246596,43.21615527328088,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-24,2.2850000858306885,2.2850000858306885,2.1449999809265137,2.2300000190734863,48093,0.0,0.0,2.2614999771118165,2.4512499809265136,2.4937583257754645,-1.3928789899241596,-7.7409487115213,-1.7045895911237692,44.59116187356979,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-27,2.2300000190734863,2.299999952316284,2.119999885559082,2.2699999809265137,33033,0.0,0.0,2.2409999847412108,2.4331249833106994,2.4955916593472165,1.2940649880750361,-7.8962239871487565,-2.503080814625611,46.81042650330324,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-28,2.494999885559082,2.494999885559082,1.9859999418258667,2.0,92151,0.0,0.0,2.205999994277954,2.413999980688095,2.4952583263317742,-9.338168395842624,-8.61640381417286,-3.2565103494969683,36.25479272445557,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-29,2.0,2.2950000762939453,2.0,2.1700000762939453,80675,0.0,0.0,2.188499999046326,2.3923749804496763,2.4967249939839045,-0.8453243207878541,-8.521865638514145,-4.179475664547332,44.70888747337758,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-30,2.234999895095825,2.265000104904175,2.0899999141693115,2.1649999618530273,24157,0.0,0.0,2.1875,2.3728749811649323,2.4968499928712844,-1.0285731724330358,-7.8122523367802925,-4.9652567058618295,44.5218587230828,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-03-31,2.140000104904175,2.549999952316284,2.075000047683716,2.134999990463257,313901,0.0,0.0,2.1859999895095825,2.3544999837875364,2.4948083251714706,-2.333028329875119,-7.156508619163315,-5.62401287378623,43.350121025009486,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-03,2.130000114440918,2.180000066757202,1.9520000219345093,2.1449999809265137,68934,0.0,0.0,2.1759999990463257,2.3344999849796295,2.493974992632866,-1.4246331862774988,-6.78946185277816,-6.394410855133717,43.88031618584337,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-04,2.424999952316284,2.424999952316284,2.0299999713897705,2.0999999046325684,63753,0.0,0.0,2.165999984741211,2.3161249816417695,2.4938916593790053,-3.0470951326681663,-6.481731257617341,-7.128083414076647,41.97643151761609,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-05,2.0899999141693115,2.0950000286102295,1.9479999542236328,1.9500000476837158,110582,0.0,0.0,2.136999988555908,2.2943749845027925,2.4930999924739203,-8.750582212148664,-6.859166309337561,-7.971000303679421,36.31958896304971,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-06,1.9500000476837158,1.9500000476837158,1.8259999752044678,1.8799999952316284,54048,0.0,0.0,2.1044999957084656,2.2742499858140945,2.492099992434184,-10.667617055578123,-7.463998732085953,-8.741623822537797,34.01580608353824,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-11,1.878000020980835,1.878000020980835,1.7339999675750732,1.75,184180,0.0,0.0,2.056499993801117,2.2522499829530718,2.4896416584650676,-14.903962787502856,-8.691308275438155,-9.535174457932001,30.18632037606703,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-12,1.690000057220459,1.7799999713897705,1.6419999599456787,1.6779999732971191,134945,0.0,0.0,1.9972999930381774,2.226949980854988,2.4875249912341437,-15.986582929655826,-10.312310100860088,-10.475272059472882,28.28690838944911,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-13,1.6779999732971191,1.7400000095367432,1.6119999885559082,1.6979999542236328,52203,0.0,0.0,1.9670999884605407,2.200774982571602,2.48537499109904,-13.680038422831089,-10.617850346427165,-11.45098866556097,29.61183028485017,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-14,1.7239999771118164,1.996000051498413,1.7000000476837158,1.7640000581741333,57272,0.0,0.0,1.9264999866485595,2.1787499845027924,2.4839083244403204,-8.434982071145486,-11.577739513411785,-12.285410734966915,33.94866764322532,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-17,1.7640000581741333,1.777999997138977,1.6720000505447388,1.746000051498413,42331,0.0,0.0,1.884599995613098,2.155274987220764,2.482324991623561,-7.354342801512938,-12.55872188990151,-13.17514852029468,33.34524704346737,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-18,1.746000051498413,1.7599999904632568,1.6200000047683716,1.7599999904632568,46288,0.0,0.0,1.8470999956130982,2.13402498960495,2.480491658051809,-4.715500262936807,-13.44524995674804,-13.967661101467902,34.323043760071755,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-19,1.7599999904632568,1.7699999809265137,1.6440000534057617,1.7000000476837158,10875,0.0,0.0,1.8026000022888184,2.1177749931812286,2.4780083249012628,-5.691776016577622,-14.882364363882122,-14.537212328953245,32.14653228944542,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-20,1.7000000476837158,1.7699999809265137,1.600000023841858,1.7640000581741333,65615,0.0,0.0,1.7690000176429748,2.108874997496605,2.476474992434184,-0.2826432684553298,-16.116411843143272,-14.843678860502296,36.75360270788552,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-21,1.7760000228881836,1.7760000228881836,1.6019999980926514,1.7680000066757202,35526,0.0,0.0,1.7508000135421753,2.096324998140335,2.474124992887179,0.982407642249575,-16.482414935884336,-15.270044796967614,37.0413209831116,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-24,1.7680000066757202,1.7680000066757202,1.7120000123977661,1.7380000352859497,39804,0.0,0.0,1.7366000175476075,2.0857749968767165,2.471191660563151,0.08061831879509444,-16.740778840094016,-15.596388974483801,35.72852316739362,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-25,1.7799999713897705,1.850000023841858,1.7380000352859497,1.7979999780654907,29361,0.0,0.0,1.7414000153541564,2.075724995136261,2.4682583262523017,3.250256242809512,-16.106419711930954,-15.903251573835325,40.28675813219188,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-26,1.7999999523162842,1.850000023841858,1.722000002861023,1.8079999685287476,40045,0.0,0.0,1.7544000148773193,2.064424994587898,2.465199993054072,3.0551728908401956,-15.017497875841507,-16.257301622399577,41.037324403761275,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-27,1.8079999685287476,1.8480000495910645,1.7039999961853027,1.7619999647140503,32642,0.0,0.0,1.760800015926361,2.0562249958515166,2.4615916599829992,0.06814793144228577,-14.367346983972212,-16.467664833341296,38.63181805845316,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-04-28,1.7619999647140503,1.8480000495910645,1.7519999742507935,1.7699999809265137,34533,0.0,0.0,1.761400008201599,2.0445999979972838,2.458008326093356,0.48824643379531196,-13.85111953795771,-16.81883351278651,39.298235671110504,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-02,1.7699999809265137,1.8480000495910645,1.6399999856948853,1.7580000162124634,68178,0.0,0.0,1.7626000046730042,2.0346749991178514,2.454199993610382,-0.260977445157454,-13.371914166282451,-17.09416492481389,38.620753704684546,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-03,1.753999948501587,1.753999948501587,1.5099999904632568,1.6480000019073486,30766,0.0,0.0,1.7514000058174133,2.022249999642372,2.448391660054525,-5.903848553535079,-13.39349703908308,-17.404962913599487,33.00396307844551,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-04,1.5839999914169312,1.6160000562667847,1.4500000476837158,1.5180000066757202,48232,0.0,0.0,1.7332000017166138,2.0053250014781954,2.44141665995121,-12.416339420018058,-13.570119534788061,-17.862238167971277,27.84913206227833,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-05,1.5180000066757202,1.5980000495910645,1.4019999504089355,1.527999997138977,60779,0.0,0.0,1.709599995613098,1.9868999987840652,2.4346916596094768,-10.622367743338433,-13.956414683208418,-18.392130233741266,28.770743140459885,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-08,1.527999997138977,1.6740000247955322,1.4780000448226929,1.6160000562667847,21804,0.0,0.0,1.6944000005722046,1.9704249978065491,2.4286999930938085,-4.627003321467424,-14.008399078453218,-18.869147963536,36.462164502770314,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-09,1.6119999885559082,1.7000000476837158,1.472000002861023,1.6979999542236328,26830,0.0,0.0,1.690399992465973,1.9537499964237213,2.4235166599353155,0.44959546802724276,-13.479206881115921,-19.38367791225056,42.673934383196865,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-10,1.6979999542236328,1.9980000257492065,1.5,1.9199999570846558,100885,0.0,0.0,1.7025999903678894,1.9404999941587449,2.4209333260854087,12.76870480128404,-12.259727106775436,-19.84496337631541,55.389698264303455,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-11,1.899999976158142,1.899999976158142,1.6260000467300415,1.7899999618530273,71011,0.0,0.0,1.7007999897003174,1.9233749955892563,2.4180999914805095,5.244589175263756,-11.572106656234734,-20.459244763834274,48.592435965422666,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-12,1.7200000286102295,1.815999984741211,1.600000023841858,1.7879999876022339,92137,0.0,0.0,1.7033999919891358,1.9093249976634978,2.414124990502993,4.966537279027863,-10.785225455402252,-20.91026748098565,48.493840404984915,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-15,1.8179999589920044,1.843999981880188,1.621999979019165,1.718000054359436,29374,0.0,0.0,1.698199999332428,1.8936499983072281,2.410233324766159,1.1659436482623728,-10.321337055396556,-21.432917765712574,45.04853838628445,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-16,1.715999960899353,1.715999960899353,1.4880000352859497,1.590000033378601,85009,0.0,0.0,1.6814000010490417,1.879025000333786,2.4069666584332783,-5.435944309112368,-10.517422559552886,-21.933899925441235,39.51950386117183,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-17,1.5839999914169312,1.6979999542236328,1.437999963760376,1.6200000047683716,19636,0.0,0.0,1.678600001335144,1.8657749980688094,2.4027166575193406,-3.491004201129666,-10.032024061175802,-22.34727335702125,41.33681674568583,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-19,1.6200000047683716,1.694000005722046,1.437999963760376,1.5700000524520874,40928,0.0,0.0,1.6838000059127807,1.8489000022411346,2.3982166588306426,-6.758519602154461,-8.929633626925677,-22.90521394582222,39.22151578209812,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-22,1.4839999675750732,1.6180000305175781,1.4299999475479126,1.6180000305175781,6924,0.0,0.0,1.6928000092506408,1.8343500018119812,2.393158326546351,-4.418713275301474,-7.7166294557481665,-23.350244676072283,42.27539755825781,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-23,1.8739999532699585,1.8739999532699585,1.4739999771118164,1.5,76644,0.0,0.0,1.6812000036239625,1.8158500015735626,2.386324993769328,-10.778015895394434,-7.415259951698451,-23.906005832620036,37.31202435308949,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-24,1.5019999742507935,1.6779999732971191,1.4780000448226929,1.4780000448226929,73775,0.0,0.0,1.6592000126838684,1.7976750046014787,2.378641660014788,-10.920923726855108,-7.70300480137723,-24.424303382027606,36.45272672891539,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-25,1.649999976158142,1.8739999532699585,1.399999976158142,1.5640000104904175,58517,0.0,0.0,1.6236000180244445,1.7810250043869018,2.367008326450984,-3.67085531364719,-8.839010456040683,-24.75628478006609,42.06922114597722,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-26,1.468000054359436,1.6799999475479126,1.4119999408721924,1.5379999876022339,93478,0.0,0.0,1.5984000205993651,1.7627250045537948,2.3533249924580257,-3.7787807944648653,-9.322213251069519,-25.096405715190016,40.892503551648076,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-29,1.5399999618530273,1.593999981880188,1.4520000219345093,1.531999945640564,42398,0.0,0.0,1.5728000164031983,1.751025003194809,2.3403833250204724,-2.5941041669073193,-10.178323351547386,-25.182127881572907,40.61020529181286,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-30,1.534000039100647,1.6160000562667847,1.4479999542236328,1.4500000476837158,73703,0.0,0.0,1.5460000157356262,1.7330250024795533,2.3266749918460845,-6.209570962147185,-10.791822765184467,-25.51495122640673,36.86463347213628,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-05-31,1.527999997138977,1.527999997138977,1.4119999408721924,1.49399995803833,94628,0.0,0.0,1.5364000082015992,1.7162500023841858,2.314083323876063,-2.7597012455694774,-10.479242181077467,-25.834563316005116,40.0593166634449,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-01,1.5,1.6480000019073486,1.399999976158142,1.4900000095367432,35748,0.0,0.0,1.5234000086784363,1.7001250028610229,2.299958324432373,-2.1924641559289424,-10.394823550338257,-26.08018220153569,39.86184726504686,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-02,1.4900000095367432,1.5140000581741333,1.399999976158142,1.50600004196167,45973,0.0,0.0,1.5170000076293946,1.6841500043869018,2.2863833248615264,-0.7251130924458086,-9.924887707277387,-26.339997931497273,41.11231331893518,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-05,1.503999948501587,1.503999948501587,1.3799999952316284,1.4600000381469727,21798,0.0,0.0,1.501200008392334,1.668150007724762,2.2727166593074797,-2.7444690923951747,-10.008092711046764,-26.601056894040433,38.62563749868898,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-07,1.4160000085830688,1.4500000476837158,1.3919999599456787,1.4079999923706055,31441,0.0,0.0,1.4920000076293944,1.6546000063419342,2.2590333263079327,-5.630027803569165,-9.827148440064573,-26.756281677077272,35.97654426523343,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-08,1.409999966621399,1.531999945640564,1.399999976158142,1.409999966621399,36786,0.0,0.0,1.485199999809265,1.6428500056266784,2.245866659283638,-5.063293374462943,-9.596129000059042,-26.850064814146318,36.15790117241412,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-09,1.409999966621399,1.5,1.409999966621399,1.4240000247955322,48576,0.0,0.0,1.4712000012397766,1.6347000062465669,2.233274993300438,-3.208263757780658,-10.001835467181682,-26.80256523936934,37.492700095496886,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-12,1.4199999570846558,1.4980000257492065,1.4199999570846558,1.4459999799728394,38754,0.0,0.0,1.4620000004768372,1.6289000064134598,2.2226999938488006,-1.0943926469753336,-10.246178726716682,-26.715255728557587,39.62876949434761,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-13,1.3899999856948853,1.49399995803833,1.350000023841858,1.3600000143051147,58404,0.0,0.0,1.4448000073432923,1.6204500079154969,2.212324993809064,-5.869323962290692,-10.839581580067133,-26.753527964917495,34.64471504803686,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-14,1.3600000143051147,1.5,1.2760000228881836,1.4279999732971191,127030,0.0,0.0,1.4425999999046326,1.6120500057935714,2.202141659458478,-1.012063400005452,-10.511460890167786,-26.796262226382584,40.966842670859855,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-15,1.4279999732971191,1.440000057220459,1.2920000553131104,1.3880000114440918,7724,0.0,0.0,1.4320000052452087,1.6031000047922135,2.1919999927282334,-3.0726252541865398,-10.673070864919747,-26.865875451169874,38.60135491454104,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-16,1.3880000114440918,1.4500000476837158,1.2920000553131104,1.3940000534057617,81580,0.0,0.0,1.4224000096321106,1.593950006365776,2.1794499923785526,-1.9966223308515159,-10.762570723582572,-26.86457537728537,39.16876135886139,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-19,1.3919999599456787,1.3919999599456787,1.3200000524520874,1.371999979019165,12297,0.0,0.0,1.40900000333786,1.5857500046491624,2.1675499926010766,-2.6259775891443238,-11.146145407100738,-26.84136421018598,37.7897616508093,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-20,1.496000051498413,1.496000051498413,1.3200000524520874,1.3600000143051147,16925,0.0,0.0,1.3990000009536743,1.5756500035524368,2.1555499931176505,-2.787704547675047,-11.211246292037577,-26.90264625811268,37.024078487769515,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-21,1.3600000143051147,1.3600000143051147,1.2899999618530273,1.350000023841858,20438,0.0,0.0,1.3932000041007995,1.5652000039815903,2.145216660698255,-3.1007737677135405,-10.989010953440676,-27.03767257372841,36.362871527872926,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-22,1.350000023841858,1.440000057220459,1.2239999771118164,1.3860000371932983,13421,0.0,0.0,1.3908000111579895,1.556400004029274,2.1359333276748655,-0.3451232331163578,-10.639937833627108,-27.13255681423633,40.48363170911826,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-26,1.3860000371932983,1.3880000114440918,1.3020000457763672,1.3600000143051147,17908,0.0,0.0,1.3844000101089478,1.5454500049352646,2.1276833285888035,-1.7624960723535972,-10.420912634638277,-27.36466070069309,38.54246853318414,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-27,1.3600000143051147,1.3600000143051147,1.3079999685287476,1.350000023841858,19111,0.0,0.0,1.3748000144958497,1.5340000063180923,2.115599995851517,-1.803898050080113,-10.378095903946868,-27.49101865541146,37.79189747273709,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-28,1.350000023841858,1.4739999771118164,1.246000051498413,1.2740000486373901,112075,0.0,0.0,1.3662000179290772,1.5218000084161758,2.1032999962568284,-6.748643542798825,-10.224733186132678,-27.647030327367865,32.59646874437793,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-29,1.2740000486373901,1.2740000486373901,1.149999976158142,1.2680000066757202,77536,0.0,0.0,1.3502000212669372,1.509250009059906,2.0917416632175447,-6.087987949673262,-10.538345988948453,-27.847208113722914,32.21987588818125,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-06-30,1.2680000066757202,1.2680000066757202,1.190000057220459,1.2580000162124634,25166,0.0,0.0,1.3372000217437745,1.496750009059906,2.0805583308140436,-5.9228241282878855,-10.6597619074907,-28.06017563207255,31.56532743154304,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-03,1.3079999685287476,1.350000023841858,1.1059999465942383,1.2979999780654907,163379,0.0,0.0,1.3276000142097473,1.4880000084638596,2.068124997615814,-2.2295899237298475,-10.779569445009725,-28.050770133368967,37.072201593279004,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-04,1.350000023841858,1.7999999523162842,1.1579999923706055,1.7000000476837158,444510,0.0,0.0,1.3604000210762024,1.4925500094890594,2.058249998092651,24.963247673199707,-8.85397390859255,-27.484513014833833,66.36538800807028,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-05,1.7000000476837158,1.7000000476837158,1.4019999504089355,1.5,55508,0.0,0.0,1.374400019645691,1.491850009560585,2.0435416638851165,9.13853161808654,-7.872774686611312,-26.99683906985643,53.11740941227114,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-06,1.444000005722046,1.7480000257492065,1.4420000314712524,1.7000000476837158,128650,0.0,0.0,1.4094000220298768,1.4939500093460083,2.032791664203008,20.61870449209336,-5.659492405180553,-26.507470703755676,61.412785690026794,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-07,1.746000051498413,2.0999999046325684,1.7100000381469727,1.8799999952316284,100667,0.0,0.0,1.4588000178337097,1.4985000103712083,2.02379166384538,28.873044437125294,-2.649315466315151,-25.955816641524848,67.06156283054585,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-10,1.8799999952316284,2.009999990463257,1.8660000562667847,2.0,73049,0.0,0.0,1.5228000164031983,1.5005000114440918,2.0162916630506516,31.3370093549074,1.4861715954033725,-25.581202415238195,70.194169115986,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-11,2.0999999046325684,2.509999990463257,2.0999999046325684,2.1500000953674316,139647,0.0,0.0,1.6028000235557556,1.509500014781952,2.0100416630506515,34.140258533171966,6.1808551083241206,-24.90205339868551,73.57699736745566,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-12,2.1500000953674316,2.240000009536743,2.0999999046325684,2.0999999046325684,41172,0.0,0.0,1.6854000091552734,1.5173000127077103,2.0031249950329464,24.599495266710804,11.078889806873388,-24.25335331194574,70.69666597153707,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-13,1.8600000143051147,2.1449999809265137,1.8600000143051147,2.015000104904175,14958,0.0,0.0,1.7601000189781189,1.5247250139713286,1.99579166273276,14.482136422795232,15.437210175605887,-23.602997124279902,65.96875174508176,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-14,2.015000104904175,2.240000009536743,1.899999976158142,1.9980000257492065,41260,0.0,0.0,1.8341000199317932,1.5349250137805939,1.9874416629473368,8.936263237351064,19.491180576588356,-22.768801600730747,65.03201917911719,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-17,2.0999999046325684,2.0999999046325684,1.4019999504089355,1.5959999561309814,76732,0.0,0.0,1.8639000177383422,1.534325012564659,1.9770749966303507,-14.37309185352286,21.480129860021712,-22.394192674546865,47.76121421548935,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-18,1.5959999561309814,1.74399995803833,1.5959999561309814,1.7380000352859497,42537,0.0,0.0,1.8677000164985658,1.5385250121355056,1.9690583298603694,-6.94436901359398,21.395492550761862,-21.864934684560307,52.55444173224005,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-19,2.0950000286102295,2.0950000286102295,1.6059999465942383,1.9160000085830688,198390,0.0,0.0,1.9093000173568726,1.545975011587143,1.9600666642189026,0.35091348480011725,23.50135047763351,-21.1264065753997,57.783604431379125,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-20,2.0250000953674316,2.0250000953674316,1.6100000143051147,1.8279999494552612,68147,0.0,0.0,1.922100007534027,1.5541750103235246,1.950924997528394,-4.895690011441822,23.673331173553837,-20.33650641144625,54.58084332926222,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-21,1.8300000429153442,1.899999976158142,1.75,1.8980000019073486,15773,0.0,0.0,1.9239000082015991,1.564675009250641,1.9428666641314825,-1.3462241376287012,22.958441646166467,-19.465651547935952,56.639637390256304,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-24,1.8980000019073486,1.8980000019073486,1.6100000143051147,1.6740000247955322,81382,0.0,0.0,1.8913000106811524,1.5674250096082687,1.9332333316405614,-11.489450888722805,20.662870573554688,-18.922098850937154,48.98733769950095,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-25,1.6779999732971191,1.8940000534057617,1.6299999952316284,1.8339999914169312,19464,0.0,0.0,1.8597000002861024,1.5748250097036363,1.9235583325227101,-1.3819438008935558,18.089310801336353,-18.129594352447672,53.78981994575498,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-26,1.899999976158142,1.899999976158142,1.659999966621399,1.7580000162124634,20279,0.0,0.0,1.8255000114440918,1.5804750114679336,1.9151666651169459,-3.6976168068183926,15.50325049103945,-17.475850000165654,51.318440281076015,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-27,1.7580000162124634,1.7580000162124634,1.649999976158142,1.6959999799728394,44813,0.0,0.0,1.7935999989509583,1.5866250097751617,1.904008330901464,-5.441571088046572,13.04498466245195,-16.669219140235334,49.327352703364575,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-28,1.6959999799728394,1.8700000047683716,1.6740000247955322,1.7640000581741333,27758,0.0,0.0,1.770200002193451,1.5933750122785568,1.8941666652758917,-0.35023974757854104,11.097512421889371,-15.879893702676032,51.5477613713962,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-07-31,1.7640000581741333,1.8380000591278076,1.656000018119812,1.7519999742507935,43469,0.0,0.0,1.785800004005432,1.599925011396408,1.8848499993483225,-1.89271081189536,11.617731536479514,-15.11658689287879,51.122038446345314,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-01,1.7920000553131104,1.7920000553131104,1.6660000085830688,1.715999960899353,43433,0.0,0.0,1.7835999965667724,1.6051750093698502,1.8746083329121273,-3.790089470595523,11.115609584961526,-14.372779572772057,49.79344393198278,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-02,1.6480000019073486,1.899999976158142,1.600000023841858,1.7799999713897705,45393,0.0,0.0,1.7699999928474426,1.6131750077009201,1.8658166656891504,0.5649705413976139,9.721510958071915,-13.540540323929177,52.17312295706091,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-03,1.7799999713897705,1.812000036239624,1.7000000476837158,1.812000036239624,22322,0.0,0.0,1.768400001525879,1.6232750087976455,1.8574166665474574,2.465507502608257,8.940259163832446,-12.605769182906679,53.36337934475558,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-04,1.812000036239624,1.812000036239624,1.649999976158142,1.6859999895095825,72852,0.0,0.0,1.7472000002861023,1.6301750093698502,1.8490916669368744,-3.5027478689616744,7.178676537403711,-11.839145753637633,48.26952997548198,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-07,1.684000015258789,1.684000015258789,1.600000023841858,1.649999976158142,24309,0.0,0.0,1.7447999954223632,1.6358250081539154,1.8409249991178513,-5.433288601154134,6.661775356486927,-11.141137800954267,46.892255387201914,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-08,1.649999976158142,1.8279999494552612,1.5499999523162842,1.649999976158142,38419,0.0,0.0,1.7263999938964845,1.640925008058548,1.8322583317756653,-4.425394926346562,5.2089513791410695,-10.442486214904735,46.892255387201914,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-09,1.649999976158142,1.7580000162124634,1.565999984741211,1.590000033378601,34155,0.0,0.0,1.709599995613098,1.6466750085353852,1.8226333330074946,-6.995786297461118,3.8213361319961203,-9.654071462731553,44.44121252826112,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-10,1.600000023841858,1.7599999904632568,1.531999945640564,1.6380000114440918,17697,0.0,0.0,1.7037999987602235,1.6519250094890594,1.814241666595141,-3.8619548869592255,3.1402750713974004,-8.94680461234846,46.835342324422115,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-11,1.6319999694824219,1.6319999694824219,1.472000002861023,1.5399999618530273,23078,0.0,0.0,1.6813999891281128,1.655725008249283,1.80470000008742,-8.409660294360311,1.5506790530377936,-8.254834145892433,42.78189196098086,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-14,1.5399999618530273,1.5920000076293945,1.4479999542236328,1.5460000038146973,56237,0.0,0.0,1.6607999920845031,1.6595250070095062,1.795833334326744,-6.912330733197927,0.07682831350004479,-7.590254881215895,43.1065499589965,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-15,1.5880000591278076,1.5880000591278076,1.4500000476837158,1.5479999780654907,28608,0.0,0.0,1.643999993801117,1.6639250069856644,1.7891500016053519,-5.839417037567205,-1.1974706252322758,-6.999133359825994,43.222194733540164,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-16,1.5479999780654907,1.600000023841858,1.4420000314712524,1.5980000495910645,42912,0.0,0.0,1.6258000016212464,1.669875007867813,1.784800002972285,-1.709924468105538,-2.6394194798354422,-6.439096532557355,46.168200199566265,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-17,1.5880000591278076,1.5880000591278076,1.4559999704360962,1.5800000429153442,51555,0.0,0.0,1.6026000022888183,1.6756250083446502,1.7790500034888586,-1.410205874279108,-4.358075684724552,-5.813495682604968,45.25779431615974,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-18,1.5,1.6480000019073486,1.5,1.600000023841858,24075,0.0,0.0,1.5940000057220458,1.6809750080108643,1.7743833363056183,0.3764126786871766,-5.174080630249106,-5.264269923163064,46.519701839708574,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-21,1.600000023841858,1.75,1.600000023841858,1.6699999570846558,37841,0.0,0.0,1.5960000038146973,1.6887250065803527,1.7699666688839595,4.636588539667082,-5.4908290221521865,-4.59001085906511,50.79500718679732,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-22,1.6979999542236328,1.75,1.6059999465942383,1.7039999961853027,45736,0.0,0.0,1.6014000058174134,1.697575005888939,1.7653333355983098,6.406893343023223,-5.665434501444213,-3.8382739589747867,52.76996603186171,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-23,1.649999976158142,1.8200000524520874,1.649999976158142,1.7400000095367432,56065,0.0,0.0,1.6164000034332275,1.7092250049114228,1.7624166697263717,7.646622484594759,-5.430823982299846,-3.0181094929842702,54.83696347761692,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-24,1.7999999523162842,1.7999999523162842,1.649999976158142,1.649999976158142,9640,0.0,0.0,1.6175999999046327,1.7187750041484833,1.7575416704018911,2.002965891160955,-5.886460066015145,-2.2057324105745506,49.05673489431648,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-25,1.6519999504089355,1.8300000429153442,1.6519999504089355,1.8300000429153442,73677,0.0,0.0,1.6466000080108643,1.7330750048160553,1.7548333376646041,11.1381048227998,-4.989685764602511,-1.2399087925640657,58.48251548684967,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-28,1.8300000429153442,1.8799999952316284,1.7400000095367432,1.7400000095367432,50491,0.0,0.0,1.6660000085830688,1.7441250056028366,1.7514583379030229,4.441776745044032,-4.479323257725137,-0.4186986433811669,53.18386655996151,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-29,1.7400000095367432,1.8739999532699585,1.7100000381469727,1.75,15164,0.0,0.0,1.6862000107765198,1.7453750044107437,1.7477500051259995,3.7836548935911436,-3.3903885116197094,-0.13588904066887134,53.68597008617509,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-30,1.75,1.75,1.6619999408721924,1.7300000190734863,18429,0.0,0.0,1.699400007724762,1.7511250048875808,1.7432916710774105,1.8006361780410443,-2.953815234117996,0.4493415496747667,52.4738235666215,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-08-31,1.7300000190734863,1.8079999685287476,1.7000000476837158,1.7699999809265137,7679,0.0,0.0,1.718400001525879,1.7528750032186509,1.7390833367904028,3.002792094670379,-1.9667689726574074,0.7930422962766979,54.677863056422794,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-01,1.7699999809265137,1.8079999685287476,1.7059999704360962,1.7960000038146973,60789,0.0,0.0,1.7379999995231628,1.7507750034332275,1.7343416700760523,3.3371694077932896,-0.7296770792942111,0.9475257177240343,56.10288423292188,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-04,1.7400000095367432,1.7920000553131104,1.656000018119812,1.6920000314712524,50458,0.0,0.0,1.7402000069618224,1.743075004220009,1.7280250032742819,-2.7697951555994575,-0.16493824139673333,0.8709365267985211,49.4105882457406,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-05,1.690000057220459,1.809999942779541,1.5,1.6360000371932983,218909,0.0,0.0,1.733400011062622,1.7302250027656556,1.721033337712288,-5.619013109940779,0.18350262491244343,0.5340782686746691,46.213888088237,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-06,1.6360000371932983,1.74399995803833,1.503999948501587,1.7280000448226929,70194,0.0,0.0,1.732200014591217,1.7209250062704087,1.7158500055472057,-0.24246448061111275,0.6551713921133394,0.2957718161142246,51.7381060227474,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-07,1.7200000286102295,1.7200000286102295,1.5520000457763672,1.621999979019165,28236,0.0,0.0,1.7294000148773194,1.7111000031232835,1.7098250051339468,-6.210248348226894,1.069488149180808,0.074568917024163,45.88992323295583,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-08,1.5720000267028809,1.6619999408721924,1.559999942779541,1.6239999532699585,17250,0.0,0.0,1.7088000059127808,1.7017500013113023,1.7052333384752274,-4.962549879997519,0.41427968832355355,-0.20427334402456795,46.013915669263845,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-11,1.5019999742507935,1.621999979019165,1.5,1.5700000524520874,21243,0.0,0.0,1.6918000102043151,1.7011000037193298,1.7004000047842662,-7.199430016407094,-0.5467046907695549,0.04116672154163938,43.13952593622887,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-12,1.7280000448226929,1.7280000448226929,1.4179999828338623,1.5959999561309814,32574,0.0,0.0,1.6764000058174133,1.6975500017404557,1.694991672039032,-4.795994357398536,-1.245912986442684,0.1509346472685717,44.92349092353159,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-13,1.6419999599456787,1.6419999599456787,1.5219999551773071,1.5299999713897705,18808,0.0,0.0,1.6564000010490418,1.687900000810623,1.6894083380699159,-7.63100878889271,-1.8662242873661472,-0.08928198265056496,41.37479727950363,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-14,1.5299999713897705,1.5299999713897705,1.4119999408721924,1.5,17473,0.0,0.0,1.6294000029563904,1.6797000020742416,1.6832416713237763,-7.941573752400055,-2.9945823096824635,-0.21040765030189448,39.83446065533703,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-15,1.496000051498413,1.7239999771118164,1.496000051498413,1.649999976158142,79563,0.0,0.0,1.6148000001907348,1.6735000014305115,1.678616671760877,2.179835023733565,-3.507618834155949,-0.304814697509119,49.88139896434808,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-18,1.659999966621399,1.659999966621399,1.6100000143051147,1.6579999923706055,12539,0.0,0.0,1.6113999962806702,1.6731000006198884,1.6738500048716862,2.8918950103943386,-3.687765484212429,-0.04480713621979079,50.35752692993512,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-19,1.6100000143051147,1.7999999523162842,1.5,1.6299999952316284,142023,0.0,0.0,1.610799992084503,1.6680000007152558,1.6685166716575623,1.1919545096520026,-3.4292571106849365,-0.030965884314076656,48.61667510133674,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-20,1.7979999780654907,1.7979999780654907,1.4199999570846558,1.565999984741211,173990,0.0,0.0,1.594599986076355,1.6631999999284743,1.664900004863739,-1.7935533415823375,-4.1245799576160165,-0.10210853086061528,44.80407163110751,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-21,1.5440000295639038,1.5540000200271606,1.4160000085830688,1.5540000200271606,46640,0.0,0.0,1.5877999901771545,1.6596500009298325,1.6597666710615158,-2.1287297114936163,-4.329226687098093,-0.007029309222641732,44.10565389896372,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-22,1.5499999523162842,1.5499999523162842,1.4199999570846558,1.5299999713897705,33141,0.0,0.0,1.5783999919891358,1.6537999987602234,1.654475004474322,-3.0663976713767283,-4.559197413690377,-0.04079878585491106,42.67291541831473,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-25,1.4199999570846558,1.527999997138977,1.4199999570846558,1.4900000095367432,20753,0.0,0.0,1.5703999876976014,1.6472499996423722,1.6491000046332678,-5.11971337179736,-4.665352069294607,-0.11218270485100229,40.32194956657916,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-26,1.4900000095367432,1.5759999752044678,1.4900000095367432,1.5299999713897705,6549,0.0,0.0,1.5637999892234802,1.6425999999046326,1.6439750045537949,-2.161402869077483,-4.797273267120871,-0.08363902403342768,43.664375573451714,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-27,1.4800000190734863,1.527999997138977,1.4299999475479126,1.527999997138977,13407,0.0,0.0,1.563599991798401,1.6363000005483628,1.639208338658015,-2.2767968052032246,-4.442951092440161,-0.17742333546406805,43.53309024883662,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-28,1.527999997138977,1.5800000429153442,1.4900000095367432,1.5360000133514404,45023,0.0,0.0,1.567199993133545,1.6293999999761581,1.6357583383719125,-1.9908103572487643,-3.81735650199603,-0.3887089092929774,44.25510353260261,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-09-29,1.5820000171661377,1.6579999923706055,1.4900000095367432,1.5119999647140503,59242,0.0,0.0,1.5533999919891357,1.62504999935627,1.6326916714509327,-2.6651234381733504,-4.409095559860736,-0.46804134719887786,42.49944378792105,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-02,1.5119999647140503,1.6080000400543213,1.406000018119812,1.6080000400543213,29812,0.0,0.0,1.5483999967575073,1.6240000009536744,1.6315083384513855,3.849137394834798,-4.655172669444082,-0.460208343454624,50.89165530385334,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-03,1.5,1.6080000400543213,1.4079999923706055,1.531999945640564,6634,0.0,0.0,1.5385999917984008,1.6210500001907349,1.6302916715542475,-0.42896439575060225,-5.086210072646303,-0.5668722673840331,45.25988350683983,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-04,1.531999945640564,1.600000023841858,1.531999945640564,1.5980000495910645,3267,0.0,0.0,1.5417999982833863,1.6212500005960464,1.6294583390156427,3.645093486201213,-4.900539847861254,-0.5037464427936834,50.393808595554724,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-05,1.5980000495910645,1.5980000495910645,1.503999948501587,1.590000033378601,8477,0.0,0.0,1.5453999996185304,1.6200500011444092,1.6280083388090134,2.8859863964721026,-4.607882563695307,-0.4888388759990131,49.78431759203393,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-06,1.399999976158142,1.600000023841858,1.399999976158142,1.5740000009536743,26440,0.0,0.0,1.5498000025749206,1.6209000021219253,1.6265750050544738,1.5614916981898683,-4.386451937437689,-0.3488927909818993,48.52037047202912,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-09,1.503999948501587,1.5980000495910645,1.503999948501587,1.5880000591278076,10513,0.0,0.0,1.559600007534027,1.6219500035047532,1.6251416722933452,1.8209830377396259,-3.844137971947258,-0.19639326484613678,49.723182564773204,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-10,1.503999948501587,1.5920000076293945,1.3020000457763672,1.5839999914169312,5360,0.0,0.0,1.5650000095367431,1.6228500038385392,1.6241750051577886,1.2140563427735844,-3.564716034443296,-0.08157995998224792,49.368260999425246,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-11,1.5839999914169312,1.5839999914169312,1.3320000171661377,1.5779999494552612,59063,0.0,0.0,1.5700000047683715,1.622350001335144,1.622625004251798,0.5095506154517468,-3.2268004144413958,-0.01694802655779732,48.80551297367541,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-12,1.49399995803833,1.49399995803833,1.409999966621399,1.465999960899353,61217,0.0,0.0,1.562999999523163,1.6194999992847443,1.6201083372036615,-6.206016548522232,-3.488731076661607,-0.03754921229324932,39.706809409857684,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-13,1.465999960899353,1.4759999513626099,1.3899999856948853,1.440000057220459,56030,0.0,0.0,1.5558000087738038,1.6155000001192092,1.617625004053116,-7.443112925845266,-3.69544978898175,-0.1313656705715036,37.938612909570864,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-16,1.496000051498413,1.496000051498413,1.3619999885559082,1.4179999828338623,88441,0.0,0.0,1.536800003051758,1.6092000007629395,1.6144583374261856,-7.730350076912027,-4.499129858119309,-0.3257028404727459,36.4591333478116,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-17,1.409999966621399,1.444000005722046,1.3619999885559082,1.3960000276565552,34527,0.0,0.0,1.523200011253357,1.6015000015497207,1.611025004585584,-8.350839197548062,-4.889165795853592,-0.5912386839901055,34.98969941904514,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-18,1.3960000276565552,1.3960000276565552,1.2480000257492065,1.3380000591278076,21679,0.0,0.0,1.4972000122070312,1.5914500027894973,1.607491672039032,-10.633178719024057,-5.922271539618868,-0.9979317173809369,31.396987849597963,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-19,1.2999999523162842,1.5679999589920044,1.1979999542236328,1.3799999952316284,170462,0.0,0.0,1.476200008392334,1.5847000032663345,1.6042416721582413,-6.516733004592838,-6.846721439412116,-1.2181250014292864,36.483003037914294,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-20,1.378000020980835,1.378000020980835,1.0540000200271606,1.2940000295639038,34406,0.0,0.0,1.4482000112533568,1.5713000029325486,1.6003750056028365,-10.647699246735911,-7.834276805794421,-1.816761856970882,31.35675199394744,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-23,1.2940000295639038,1.2940000295639038,1.065999984741211,1.1519999504089355,273702,0.0,0.0,1.4046000003814698,1.5566000014543533,1.5962416718403498,-17.98377117356768,-9.76487221706718,-2.483437883205529,25.088355277189734,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-24,1.1480000019073486,1.2660000324249268,1.0720000267028809,1.1959999799728394,116857,0.0,0.0,1.3657999992370606,1.5427500009536743,1.5935583382844924,-12.432275542471226,-11.469778098021672,-3.188357533588299,29.773019463596796,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-25,1.1959999799728394,1.2419999837875366,1.0720000267028809,1.1959999799728394,16430,0.0,0.0,1.3276000022888184,1.529399999976158,1.5907916714747747,-9.912625948259793,-13.194716731429684,-3.85918989893267,29.773019463596796,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-26,1.1959999799728394,1.2380000352859497,1.1100000143051147,1.215999960899353,19821,0.0,0.0,1.3026000022888184,1.515549999475479,1.5874583373467128,-6.6482451433516925,-14.05100440502531,-4.529777958861065,32.014282344150814,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-27,1.24399995803833,1.24399995803833,1.1239999532699585,1.2000000476837158,17168,0.0,0.0,1.278600001335144,1.5006500005722045,1.5833083381255468,-6.147345031233555,-14.796921277605835,-5.220608997183717,31.157589032931455,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-30,1.2000000476837158,1.2000000476837158,1.0740000009536743,1.1979999542236328,19742,0.0,0.0,1.2565999984741212,1.4882999986410141,1.5772916714350382,-4.663380894608142,-15.568097855167723,-5.642055582088913,31.045748023106796,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-10-31,1.2419999837875366,1.2419999837875366,1.0980000495910645,1.2000000476837158,23015,0.0,0.0,1.2370000004768371,1.4773999989032744,1.5723750054836274,-2.9911037007969767,-16.271828794158296,-6.040226170546433,31.311274221976504,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-01,1.1799999475479126,1.2000000476837158,1.00600004196167,1.1959999799728394,25178,0.0,0.0,1.2227999925613404,1.464099997282028,1.5674416720867157,-2.191692243337716,-16.481115030984206,-6.593015653788896,31.05372410379779,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-02,1.1959999799728394,1.2480000257492065,1.121999979019165,1.2100000381469727,11881,0.0,0.0,1.2057999968528748,1.4537999987602235,1.5632083386182785,0.3483198959246943,-17.05874275133024,-6.998960864983688,33.12700880004225,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-03,1.2100000381469727,1.2100000381469727,1.1059999465942383,1.1820000410079956,32618,0.0,0.0,1.194599997997284,1.4427500009536742,1.5598083386818569,-1.0547427599541093,-17.199792257311408,-7.504661619331053,31.11194796150845,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-06,1.1239999532699585,1.1820000410079956,1.1239999532699585,1.1699999570846558,18127,0.0,0.0,1.196399998664856,1.4327499985694885,1.5560583382844926,-2.2066233374842654,-16.49624848303007,-7.924403390360533,30.262338378063063,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-07,1.187999963760376,1.25,1.1200000047683716,1.149999976158142,62505,0.0,0.0,1.1917999982833862,1.4215999990701675,1.5525583376487095,-3.50730174403851,-16.164884702946512,-8.435002756603234,28.848358321350617,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-08,1.149999976158142,1.444000005722046,1.149999976158142,1.2200000286102295,45644,0.0,0.0,1.1942000031471252,1.413850000500679,1.5492416709661483,2.1604442635331145,-15.535594106572159,-8.739222098320873,39.50277593930087,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-09,1.2680000066757202,1.2699999809265137,1.2020000219345093,1.2480000257492065,36432,0.0,0.0,1.1974000096321107,1.407550001144409,1.547141671180725,4.2258239276816285,-14.930197246381008,-9.022552532618713,43.16864625173912,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-10,1.2480000257492065,1.4040000438690186,1.2480000257492065,1.25,29825,0.0,0.0,1.202400004863739,1.3975500017404556,1.5452416708072028,3.958748747814179,-13.963721987312377,-9.557836282631184,43.43231650991936,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-13,1.25,1.25,1.184000015258789,1.2000000476837158,38078,0.0,0.0,1.2026000142097473,1.3861000031232833,1.5422083377838134,-0.2161954511317664,-13.238582245152413,-10.122389487587723,38.60953503531876,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-14,1.2000000476837158,1.3980000019073486,1.190000057220459,1.2860000133514404,93235,0.0,0.0,1.2112000107765197,1.3775000035762788,1.5401083379983902,6.175693684725549,-12.07259472726021,-10.558239989366344,49.082407654318416,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-15,1.2860000133514404,1.4579999446868896,1.2000000476837158,1.2359999418258667,45978,0.0,0.0,1.2152000069618225,1.3692500025033951,1.5376416712999343,1.7116470329890028,-11.250684335214427,-10.951294566189766,44.34573091156188,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-16,1.312000036239624,1.312000036239624,1.1419999599456787,1.2079999446868896,11015,0.0,0.0,1.2149999976158141,1.3606000006198884,1.5356250037749608,-0.576136044663426,-10.701161468303617,-11.397639575079593,41.90677381004693,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-17,1.2079999446868896,1.2359999418258667,1.100000023841858,1.2000000476837158,34001,0.0,0.0,1.2167999982833861,1.352350002527237,1.5331750045220056,-1.3806665535314788,-10.023293081712465,-11.794152752388758,41.209409325423266,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-20,1.156000018119812,1.3459999561309814,1.0980000495910645,1.194000005722046,80623,0.0,0.0,1.2192000031471253,1.3449500024318695,1.53070833782355,-2.06692891732534,-9.349789884930257,-12.13544937344514,40.66286157466013,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-21,1.3279999494552612,1.9520000219345093,1.2999999523162842,1.7400000095367432,1173245,0.0,0.0,1.2782000064849854,1.350200003385544,1.5326583375533422,36.12893136510732,-5.332543083989252,-11.904697198141728,74.19826964866421,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-22,1.781999945640564,2.200000047683716,1.5499999523162842,1.7000000476837158,510784,0.0,0.0,1.326200008392334,1.3545000046491622,1.5346583376328151,28.185796782230106,-2.0893315732515174,-11.739312169088016,71.03105933132288,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-23,1.7000000476837158,1.9500000476837158,1.562000036239624,1.9500000476837158,300535,0.0,0.0,1.396400010585785,1.3648500055074693,1.5391750047604242,39.6448032727884,2.311609697109905,-11.325872543004882,77.49650208279523,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-24,1.9600000381469727,2.0450000762939453,1.7799999713897705,1.8459999561309814,142663,0.0,0.0,1.4560000061988831,1.3732000052928925,1.5428083380063375,26.78571073294529,6.029711665223161,-10.993480430149729,70.45219055909166,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-27,1.8459999561309814,1.8459999561309814,1.600000023841858,1.7239999771118164,169790,0.0,0.0,1.5083999991416932,1.3761000037193298,1.5453083376089731,14.293289451922798,9.614126521675917,-10.949810453456571,63.1952793558102,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-28,1.7239999771118164,1.7979999780654907,1.6699999570846558,1.7580000162124634,63423,0.0,0.0,1.5555999994277954,1.3817500054836274,1.5479083379109702,13.011057910717271,12.581870327789044,-10.734378022124174,64.29895776477319,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-29,1.7960000038146973,1.9980000257492065,1.694000005722046,1.8980000019073486,150208,0.0,0.0,1.6218000054359436,1.3892500042915343,1.5523916711409886,17.03045970807984,16.739247826239964,-10.50905321654729,68.48913679813916,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-11-30,1.8700000047683716,1.9780000448226929,1.7319999933242798,1.784000039100647,172632,0.0,0.0,1.6794000148773194,1.3941000044345855,1.555358338356018,6.228416297291068,20.464816694297692,-10.367921651539117,62.09783206620057,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-01,1.8040000200271606,1.8040000200271606,1.7319999933242798,1.7899999618530273,98144,0.0,0.0,1.7384000062942504,1.3995000034570695,1.558708337942759,2.9682440964075143,24.21579149696493,-10.21411964061337,62.29725104193031,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-04,1.7899999618530273,1.7999999523162842,1.7079999446868896,1.7799999713897705,49386,0.0,0.0,1.797000002861023,1.4043000012636184,1.5619250039259593,-0.9460228961706436,27.96411032144448,-10.091713895746873,61.714439918651024,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-05,1.7100000381469727,1.7799999713897705,1.690000057220459,1.7799999713897705,49356,0.0,0.0,1.8009999990463257,1.4092000007629395,1.565325003862381,-1.1660204146404893,27.803008662451468,-9.97396724093775,61.714439918651024,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-06,1.7599999904632568,1.7599999904632568,1.5859999656677246,1.687999963760376,28986,0.0,0.0,1.7997999906539917,1.4119500011205672,1.5680583367745082,-6.211802837769268,27.469102250477327,-9.955518362604762,56.113229857120686,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-07,1.6460000276565552,1.6959999799728394,1.5499999523162842,1.5499999523162842,72107,0.0,0.0,1.7597999811172484,1.4140500009059906,1.5697250028451284,-11.921811061037063,24.451043456011714,-9.917342315181106,48.93826787001348,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-08,1.7719999551773071,1.7719999551773071,1.4019999504089355,1.531999945640564,82748,0.0,0.0,1.7283999800682068,1.4163499981164933,1.5709416687488555,-11.363112514031181,22.03198237488526,-9.840700880732484,48.0747924440334,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-11,1.5980000495910645,1.5980000495910645,1.5,1.5540000200271606,49315,0.0,0.0,1.7113999843597412,1.4197499990463256,1.572558335463206,-9.197146533308288,20.542347984456608,-9.71718078565714,49.25333444888868,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-12,1.6299999952316284,1.6299999952316284,1.5160000324249268,1.5180000066757202,21861,0.0,0.0,1.687399983406067,1.4227999985218047,1.5739583353201547,-10.039112148644675,18.597131371883897,-9.603706362888143,47.359101128884234,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-13,1.600000023841858,1.8179999589920044,1.4620000123977661,1.7139999866485596,159095,0.0,0.0,1.668999981880188,1.4321999967098236,1.577625001470248,2.696225599575952,16.53400263331673,-9.217970343072492,57.045176088454916,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-14,1.7100000381469727,1.7100000381469727,1.600000023841858,1.6519999504089355,111474,0.0,0.0,1.655799973011017,1.4389999955892563,1.580825001001358,-0.2294976847457685,15.066016545259483,-8.97158163125356,53.68036571026179,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-15,1.8619999885559082,2.674999952316284,1.8619999885559082,2.0199999809265137,855426,0.0,0.0,1.6787999749183655,1.4571499943733215,1.5871750007073084,20.324041643182632,15.211198668697751,-8.192228725631555,66.36278899639107,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-18,2.0250000953674316,2.494999885559082,2.0199999809265137,2.390000104904175,358673,0.0,0.0,1.7397999882698059,1.4880999982357026,1.5962750017642975,37.372118692849234,16.91418522495261,-6.776714752096817,74.05470363980686,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-19,2.444999933242798,2.5950000286102295,2.4000000953674316,2.509999990463257,119001,0.0,0.0,1.8127999901771545,1.5209499984979629,1.6030250012874603,38.45984135392504,19.18866445099527,-5.120007655749558,75.97366262923751,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-20,2.505000114440918,2.509999990463257,2.2149999141693115,2.494999885559082,98811,0.0,0.0,1.893499982357025,1.553424996137619,1.6113166670004526,31.76656502807626,21.891947603840325,-3.5928177277903983,75.22469057169957,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-21,2.494999885559082,5.440000057220459,2.494999885559082,3.755000114440918,2353672,0.0,0.0,2.1139999985694886,1.6168999999761582,1.6284416675567628,77.6253603113467,30.74401624099575,-0.7087553586074208,86.90378768710195,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-22,3.9000000953674316,5.0,3.6449999809265137,4.289999961853027,1504788,0.0,0.0,2.3898000001907347,1.6941499978303909,1.648525000611941,79.51292834172877,41.061889634992546,2.767625434950255,89.22614493904442,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-27,4.349999904632568,4.84499979019165,3.805000066757202,3.9049999713897705,754706,0.0,0.0,2.624899995326996,1.7618249982595444,1.6644000003735224,48.76757127287459,48.98755539965991,5.8534605782358815,78.44553582885322,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-28,3.9000000953674316,4.199999809265137,3.359999895095825,3.7950000762939453,417789,0.0,0.0,2.8526000022888183,1.8266999989748,1.6781083335479101,33.03653064744377,56.16138412929242,8.854712324366611,75.63374499711237,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2023-12-29,3.7950000762939453,4.090000152587891,3.7100000381469727,3.994999885559082,129556,0.0,0.0,3.080699992179871,1.8966749966144563,1.693900000055631,29.67831647677781,62.42635125569146,11.970895362900155,77.23170972965598,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-02,3.994999885559082,4.0,3.5,3.7300000190734863,272504,0.0,0.0,3.2884999990463255,1.959674996137619,1.708191666007042,13.4255745827945,67.80843790565919,14.722196293020684,70.62287967391111,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-03,3.7300000190734863,3.7300000190734863,3.509999990463257,3.640000104904175,47922,0.0,0.0,3.450500011444092,2.0211249977350234,1.721875,5.491960377672164,70.72175225732697,17.379310213286292,68.47963623335389,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-04,3.640000104904175,3.815000057220459,3.5,3.7950000762939453,74851,0.0,0.0,3.5910000085830687,2.0867500007152557,1.740200001001358,5.6808707107569925,72.08577967424058,19.914377629840445,70.15925218177205,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-05,4.199999809265137,4.840000152587891,4.125,4.260000228881836,205615,0.0,0.0,3.7660000324249268,2.164500007033348,1.7612166692813238,13.117371009124037,73.98937492204428,22.897996866937824,74.54202349982775,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-08,4.0,4.0,3.799999952316284,4.0,156217,0.0,0.0,3.9165000438690187,2.2340000063180923,1.7785833358764649,2.1320044732718455,75.3133407695864,25.605585144943653,68.4852482181374,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-09,3.994999885559082,4.300000190734863,3.819999933242798,4.039999961853027,236736,0.0,0.0,3.9450000286102296,2.3038000047206877,1.7970166693131129,2.408109823924766,71.23882370546833,28.201370864371917,68.90386556260646,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-10,4.050000190734863,4.360000133514404,3.994999885559082,4.300000190734863,164631,0.0,0.0,3.9460000514984133,2.3800500094890595,1.8170333375533423,8.971113396261252,65.79483774567939,30.985489385342053,71.54928950867846,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-11,4.300000190734863,4.360000133514404,4.0,4.239999771118164,148908,0.0,0.0,3.9795000314712525,2.4560500025749206,1.8384166687726975,6.546041904429957,62.02846144415416,33.595938521083305,70.06788679595718,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-12,4.199999809265137,4.295000076293945,4.0,4.050000190734863,163658,0.0,0.0,4.005000042915344,2.5251500070095063,1.8568833371003468,1.1235991844525035,58.60444059948738,35.98861902399882,65.44684831643427,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-15,4.239999771118164,4.239999771118164,4.054999828338623,4.210000038146973,44947,0.0,0.0,4.0265000581741335,2.599500009417534,1.877316670616468,4.557307272362229,54.895173825229016,38.46891417439538,67.39683623551451,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-16,4.210000038146973,4.300000190734863,4.03000020980835,4.195000171661377,61883,0.0,0.0,4.073000073432922,2.674175015091896,1.8981416722138722,2.9953374915023505,52.30865782705537,40.88384730381625,67.01500730446553,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-17,4.195000171661377,4.25,3.990000009536743,4.0,98587,0.0,0.0,4.1090000629425045,2.7441750138998033,1.9167750050624213,-2.6527150467953087,49.735350046173636,43.16625616737094,62.09024810306715,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-18,4.0,4.449999809265137,4.0,4.440000057220459,114919,0.0,0.0,4.173500061035156,2.8253250151872633,1.939175005753835,6.385527549727711,47.71752058969879,45.697268519039426,67.83418784369513,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-19,4.445000171661377,4.699999809265137,4.400000095367432,4.690000057220459,203225,0.0,0.0,4.2165000438690186,2.8990750163793564,1.9639583398898444,11.229693073048365,45.44294369915923,47.61387538097989,70.56329212092402,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-22,4.715000152587891,5.199999809265137,4.715000152587891,4.900000095367432,204006,0.0,0.0,4.306500053405761,2.979075017571449,1.9899583409229915,13.781493895310776,44.55829504140628,49.7053961536542,72.66157100966497,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-23,4.914999961853027,5.179999828338623,4.320000171661377,4.485000133514404,307553,0.0,0.0,4.351000070571899,3.0424500197172164,2.0122333417336145,3.079753177868641,43.00974682819301,51.19767457466099,63.090676608283985,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-24,4.489999771118164,4.84499979019165,4.364999771118164,4.599999904632568,84114,0.0,0.0,4.38100004196167,3.1113000184297563,2.0365166743596395,4.998855525526025,40.80930852090307,52.77557299687079,64.48663714895577,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-25,4.599999904632568,4.795000076293945,4.400000095367432,4.590000152587891,48891,0.0,0.0,4.416000080108643,3.182950022816658,2.0610166758298876,3.9402189611139478,38.73922142832873,54.43591796922329,64.2590497062931,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-26,4.590000152587891,4.605000019073486,4.15500020980835,4.375,90618,0.0,0.0,4.448500061035157,3.2483750224113463,2.083725009361903,-1.6522436782445113,36.94539670893445,55.892692549008316,59.40467382116016,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-29,4.199999809265137,4.199999809265137,3.565000057220459,3.9000000953674316,232049,0.0,0.0,4.417500066757202,3.2984250247478486,2.1029750098784765,-11.714769973272613,33.92755735276724,56.84565956580021,50.354148337037785,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-30,3.6600000858306885,3.994999885559082,3.640000104904175,3.7799999713897705,77962,0.0,0.0,4.3760000467300415,3.3483250230550765,2.1208250095446903,-13.61974563472939,30.692212273266545,57.878420331053725,48.350032561817436,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-01-31,4.800000190734863,5.639999866485596,3.8499999046325684,3.930000066757202,2075650,0.0,0.0,4.369000053405761,3.401825025677681,2.1407416770855585,-10.048065490554208,28.43106333887377,58.90871197074943,50.97658247910549,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-01,4.09499979019165,4.275000095367432,3.6449999809265137,3.8350000381469727,248066,0.0,0.0,4.308500051498413,3.453200027346611,2.1598166773716607,-10.989903857301018,24.768331326841853,59.883941240277096,49.26776623697966,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-02,3.684999942779541,4.0,3.299999952316284,3.700000047683716,449324,0.0,0.0,4.209500050544738,3.5012000292539596,2.1777500112851462,-12.103575169100896,20.230207225312526,60.77143892139445,46.86365009978834,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-05,3.684999942779541,3.950000047683716,2.799999952316284,3.299999952316284,386725,0.0,0.0,4.049500036239624,3.5415000289678575,2.191933343807856,-18.508459741102445,14.344204521150855,61.56969549153881,40.54982438513225,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-06,3.194999933242798,3.450000047683716,2.8499999046325684,3.4000000953674316,329561,0.0,0.0,3.9410000324249266,3.587750032544136,2.2071000109116237,-13.727478624876174,9.846003670169152,62.55493701267514,42.63076989969746,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-07,3.4000000953674316,3.4000000953674316,3.015000104904175,3.140000104904175,163367,0.0,0.0,3.7950000524520875,3.6279500365257262,2.2199333449204763,-17.25955042147347,4.604529120978061,63.42607965356224,38.825527505908376,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-08,3.140000104904175,3.484999895095825,2.609999895095825,2.950000047683716,274511,0.0,0.0,3.63100004196167,3.66285003721714,2.2306000123421352,-18.755163492370542,-0.8695413388987225,64.20918214606925,36.2771849168691,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-09,2.9549999237060547,2.990000009536743,2.4000000953674316,2.930000066757202,467832,0.0,0.0,3.48650004863739,3.6981500387191772,2.240816679596901,-15.961565298061068,-5.723131508073977,65.03581361168888,36.00925873089077,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-12,2.930000066757202,2.930000066757202,2.2049999237060547,2.4149999618530273,508803,0.0,0.0,3.33800003528595,3.715675038099289,2.2464416791995365,-27.65129010413128,-10.16437118264612,65.40269317934295,29.887998590226744,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-13,2.3299999237060547,2.5950000286102295,2.130000114440918,2.244999885559082,185230,0.0,0.0,3.1845000267028807,3.7305000364780425,2.2514000117778776,-29.50228083736347,-14.636107879270774,65.69690046026759,28.184789623346674,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-14,2.244999885559082,2.5899999141693115,2.0450000762939453,2.1700000762939453,127021,0.0,0.0,3.008500027656555,3.7342500388622284,2.254233345389366,-27.871030202906528,-19.434960263849895,65.65499070892432,27.441805541416542,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-15,2.1700000762939453,2.3949999809265137,2.015000104904175,2.1500000953674316,111905,0.0,0.0,2.840000033378601,3.72825003862381,2.2576500127712884,-24.29577217963312,-23.824850695182562,65.13852977802105,27.235621000629152,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-16,2.1449999809265137,2.25,2.049999952316284,2.200000047683716,75289,0.0,0.0,2.690000033378601,3.720500040054321,2.261400013168653,-18.215612625084336,-27.69788994977874,64.52197834920814,28.67836540121361,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-19,2.200000047683716,2.200000047683716,2.0999999046325684,2.0999999046325684,21156,0.0,0.0,2.5700000286102296,3.7106250405311583,2.264483345548312,-18.287942363635757,-30.739430674398015,63.8618825713944,27.503795377557793,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-20,2.1050000190734863,2.3949999809265137,2.1050000190734863,2.194999933242798,57263,0.0,0.0,2.449500012397766,3.6716250360012053,2.268025011817614,-10.389878663680557,-33.28567083022359,61.886443794494774,30.41934752840224,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-21,2.194999933242798,3.0,2.194999933242798,2.4549999237060547,210299,0.0,0.0,2.3809999942779543,3.625750035047531,2.273516677816709,3.107934884751695,-34.33082889712388,59.47760887021034,37.79294558796273,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-22,2.5,2.8499999046325684,2.2899999618530273,2.7950000762939453,143836,0.0,0.0,2.365499997138977,3.5980000376701353,2.282708344856898,18.156841246013094,-34.25514251326292,57.619787292436264,45.87107536186832,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-23,2.7950000762939453,2.8499999046325684,2.4549999237060547,2.6649999618530273,156069,0.0,0.0,2.3389999866485596,3.5697500348091125,2.2912833442290625,13.937579181929685,-34.47720529895213,55.79697045326403,43.54278725366361,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-26,2.6649999618530273,2.6649999618530273,2.4000000953674316,2.494999885559082,47593,0.0,0.0,2.346999979019165,3.5322500348091124,2.297675009568532,6.305918528459789,-33.55510068963733,53.731490315177965,40.63796342395079,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-27,2.494999885559082,2.5199999809265137,2.299999952316284,2.484999895095825,70324,0.0,0.0,2.370999979972839,3.501125031709671,2.304866675535838,4.808094309823315,-32.27891153561484,51.9014122973393,40.46694647231165,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-28,2.484999895095825,2.515000104904175,2.2200000286102295,2.2699999809265137,65912,0.0,0.0,2.380999970436096,3.4668750286102297,2.3102500090996423,-4.661906379161019,-31.321436429435696,50.064928685417506,36.87399913982988,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-02-29,2.484999895095825,2.484999895095825,2.200000047683716,2.2799999713897705,21785,0.0,0.0,2.39399995803833,3.429000025987625,2.31616667509079,-4.761904287666418,-30.183728786971738,48.04634152044408,37.15349637759333,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-01,2.2799999713897705,2.3499999046325684,2.009999990463257,2.1449999809265137,126121,0.0,0.0,2.38849995136261,3.3761250197887422,2.3207416752974193,-10.194681825184151,-29.25321374763343,45.47612324650775,34.9065388314302,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-04,2.1449999809265137,2.2950000762939453,2.0,2.134999990463257,137916,0.0,0.0,2.3919999599456787,3.3295000195503235,2.3257833421230316,-10.744146061284141,-28.15738261299851,43.15606958088688,34.73894334709772,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-05,2.134999990463257,2.375,1.7660000324249268,1.940000057220459,121488,0.0,0.0,2.366499972343445,3.2770000219345095,2.3294500092665356,-18.02239256739315,-27.784560375241302,40.67698421939199,31.557144080053547,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-06,1.940000057220459,2.2249999046325684,1.940000057220459,2.134999990463257,42312,0.0,0.0,2.334499979019165,3.222875016927719,2.3334916760524114,-8.54572672301876,-27.56467542931337,38.11384244489294,37.70204193983116,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-07,2.200000047683716,2.5,2.0299999713897705,2.194999933242798,179080,0.0,0.0,2.2744999647140505,3.171750020980835,2.3379666755596795,-3.495275124405084,-28.28880114547357,35.662755767105125,39.50186410278407,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-08,2.0999999046325684,2.255000114440918,2.0199999809265137,2.244999885559082,99720,0.0,0.0,2.2324999570846558,3.1266250133514406,2.3430916746457418,0.5599072212637125,-28.59713117014851,33.44014863712763,41.030783457748385,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-11,2.244999885559082,2.255000114440918,2.0199999809265137,2.255000114440918,132611,0.0,0.0,2.2084999799728395,3.077750015258789,2.3488333423932395,2.105507579341264,-28.24303569089121,31.033137162590346,41.35003673426566,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-12,2.240000009536743,2.25,2.075000047683716,2.244999885559082,50950,0.0,0.0,2.184499979019165,3.0290000081062316,2.3545916746060054,2.769508222521535,-27.880489495774498,28.642262723241608,41.1103489768106,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-13,2.255000114440918,2.255000114440918,2.0,2.065000057220459,125069,0.0,0.0,2.1639999866485597,2.9806250095367433,2.3590500086545942,-4.574858134884945,-27.397777992042872,26.348530069383465,36.95773008022674,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-14,2.0199999809265137,2.2300000190734863,2.0199999809265137,2.1050000190734863,59126,0.0,0.0,2.146499991416931,2.922250008583069,2.364175008734067,-1.9333786400833004,-26.54632611472832,23.60548596391057,38.44572451175706,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-15,2.0950000286102295,2.1449999809265137,1.940000057220459,2.1449999809265137,31591,0.0,0.0,2.146499991416931,2.8586250066757204,2.36930000881354,-0.06988169095809336,-24.911452659784697,20.65272426632103,39.97157196743431,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-18,1.940000057220459,2.134999990463257,1.940000057220459,2.065000057220459,76385,0.0,0.0,2.1394999980926515,2.787750005722046,2.3737750093142194,-3.4821192305963367,-23.253520089635632,17.439521217616296,37.945619638654755,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-19,2.0,2.0450000762939453,1.899999976158142,1.9539999961853027,61088,0.0,0.0,2.140899991989136,2.7244750022888184,2.3772583425045015,-8.729973212348984,-21.419723425960015,14.605760492084988,35.27413492293425,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-20,1.9520000219345093,1.9520000219345093,1.75,1.8020000457763672,93520,0.0,0.0,2.1075999975204467,2.6545250058174132,2.3796750098466872,-14.499902832777204,-20.60349806833147,11.549896302370865,31.956316110792116,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-21,1.8359999656677246,2.1549999713897705,1.809999942779541,1.899999976158142,117269,0.0,0.0,2.0781000018119813,2.5872750014066694,2.3821083426475527,-8.570329892620492,-19.679972145127827,8.612818110996912,36.12766117184043,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-22,1.899999976158142,2.109999895095825,1.7999999523162842,2.049999952316284,70693,0.0,0.0,2.0586000084877014,2.529150000214577,2.3864250093698502,-0.417762369375246,-18.60506461407798,5.980702946220545,41.98963656650233,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-25,1.9500000476837158,2.049999952316284,1.9500000476837158,1.9900000095367432,57220,0.0,0.0,2.032099997997284,2.4813999980688095,2.3896916757027307,-2.0717478717598588,-18.10671396877572,3.8376633813694987,40.3927328245357,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-26,1.9900000095367432,2.184999942779541,1.9520000219345093,2.1449999809265137,51896,0.0,0.0,2.022100007534027,2.440524998307228,2.39431667526563,6.077838530961895,-17.14487624848852,1.9299169370096587,46.09599245452953,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-27,2.1449999809265137,3.4749999046325684,2.1449999809265137,2.555000066757202,359092,0.0,0.0,2.0711000084877016,2.406149998307228,2.4024916758139927,23.36439844944233,-13.924734121116325,0.15227201534406587,57.6412594975051,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-03-28,2.869999885559082,2.869999885559082,2.3450000286102295,2.509999990463257,26448,0.0,0.0,2.1116000056266784,2.3730249971151354,2.4101750085751217,18.867208930431016,-11.016529189800737,-1.5413823198651924,56.21803766857186,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-02,2.5999999046325684,2.5999999046325684,2.1500000953674316,2.3399999141693115,61493,0.0,0.0,2.1310999989509583,2.339024993777275,2.4164750079313913,9.802445465777533,-8.88938747467337,-3.2050823575625125,51.086303372304485,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-03,2.240000009536743,2.490000009536743,2.200000047683716,2.390000104904175,49832,0.0,0.0,2.16360000371933,2.3162749975919725,2.4232416758934656,10.464046071161604,-6.591401885845392,-4.414197699123582,52.46081199122248,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-04,2.390000104904175,2.740000009536743,2.2699999809265137,2.440000057220459,88675,0.0,0.0,2.2122000098228454,2.292274996638298,2.4313583433628083,10.297443557820795,-3.4932539478415743,-5.720396876264002,53.85719197335627,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-05,2.5,2.690000057220459,2.309999942779541,2.5999999046325684,42110,0.0,0.0,2.2919999957084656,2.278774991631508,2.4410250087579093,13.438041426736516,0.5803558545940137,-6.646798641729634,58.098644310400616,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-08,2.5899999141693115,3.0,2.4600000381469727,2.5399999618530273,46292,0.0,0.0,2.355999994277954,2.2685249894857407,2.4503750085830687,7.809845841339405,3.8560300282186115,-7.421313817695315,56.01912552858089,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-09,2.8399999141693115,2.8399999141693115,2.3499999046325684,2.7200000286102295,50394,0.0,0.0,2.4230000019073485,2.2632749885320664,2.4614083419243493,12.257533077552086,7.057251734084592,-8.049592991847122,60.57785304596575,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-10,2.7100000381469727,2.7100000381469727,2.430000066757202,2.640000104904175,11648,0.0,0.0,2.488000011444092,2.268899992108345,2.4722583423058193,6.109328487175472,9.656662704298,-8.225610839998483,57.714554002079154,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-11,2.640000104904175,2.700000047683716,2.4800000190734863,2.690000057220459,87278,0.0,0.0,2.5425000190734863,2.2800249963998795,2.4831750094890594,5.801378054688205,11.511936188772069,-8.181059019717674,59.01834222562804,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-12,2.690000057220459,2.700000047683716,2.5,2.559999942779541,94331,0.0,0.0,2.54300000667572,2.2897749930620193,2.4937250087658565,0.6684992551786768,11.058947467806597,-8.178528706530155,54.32805813848106,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-15,2.690000057220459,2.690000057220459,2.440000057220459,2.490000009536743,40026,0.0,0.0,2.541000008583069,2.2982749909162523,2.5048750092585883,-2.0070837809545967,10.561182566323339,-8.247917264482071,51.93469655857681,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-16,2.5899999141693115,2.5899999141693115,2.4000000953674316,2.5,29358,0.0,0.0,2.557000017166138,2.305774989724159,2.515741676092148,-2.229175470609091,10.89547022417972,-8.346114720893864,52.25826708472602,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-17,2.5,2.630000114440918,2.3299999237060547,2.4200000762939453,16933,0.0,0.0,2.560000014305115,2.3137749940156938,2.5259416768948237,-5.4687475480023044,10.64170115617349,-8.399508382155108,49.393547258515426,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-18,2.4200000762939453,2.5799999237060547,2.3499999046325684,2.4800000190734863,8478,0.0,0.0,2.5640000104904175,2.3208999961614607,2.5364750107129415,-3.2761306970846866,10.474385571589478,-8.499000133688991,51.53922005865805,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-19,1.5,1.899999976158142,0.8999999761581421,1.600000023841858,1530600,0.0,0.0,2.4640000224113465,2.299524998664856,2.5398083438475925,-35.06493468794499,7.1525651533246,-9.460688077696748,30.86752970211043,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-22,1.6050000190734863,1.6950000524520874,1.5149999856948853,1.590000033378601,73490,0.0,0.0,2.369000029563904,2.2693999975919725,2.543075011173884,-32.88307245520401,4.38882665363601,-10.761578497662287,30.716759628276705,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-23,1.534999966621399,1.534999966621399,1.2599999904632568,1.4450000524520874,93277,0.0,0.0,2.2415000319480898,2.2388999998569488,2.545116677880287,-35.53423904276118,0.11612988928970203,-12.031537912767616,28.53995431400807,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-24,1.440000057220459,1.5449999570846558,1.2899999618530273,1.3899999856948853,109713,0.0,0.0,2.1165000200271606,2.211275002360344,2.5467333445946374,-34.32553874121638,-4.285988049067589,-13.172103115793151,27.737012945381082,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-25,1.5,1.559999942779541,1.3350000381469727,1.4500000476837158,40968,0.0,0.0,1.9925000190734863,2.1854000061750414,2.5487333446741105,-27.227099934585357,-8.826758788162309,-14.255447289466295,30.049063156539177,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-26,1.4950000047683716,1.5449999570846558,1.3550000190734863,1.5,37251,0.0,0.0,1.8865000247955321,2.166150006651878,2.5513833443323772,-20.48767663480009,-12.91000073852635,-15.098998687761028,32.00152737738537,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-29,1.440000057220459,1.4500000476837158,1.3300000429153442,1.399999976158142,197057,0.0,0.0,1.7775000214576722,2.1441500067710875,2.5533000111579893,-21.23769568171111,-17.100015584523394,-16.02436073312597,30.18675888148158,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-04-30,1.3949999809265137,1.3949999809265137,1.2999999523162842,1.3450000286102295,60395,0.0,0.0,1.662000024318695,2.1241500079631805,2.55492501159509,-19.073404998198697,-21.756937217802008,-16.86057327228435,29.205765727051215,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-02,1.3450000286102295,1.3450000286102295,1.2549999952316284,1.2949999570846558,119527,0.0,0.0,1.549500012397766,2.1031500071287157,2.5555500109990437,-16.424656552231028,-26.32479817675057,-17.702647254923836,28.305213389290316,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-03,1.2949999570846558,1.399999976158142,1.2949999570846558,1.309999942779541,34144,0.0,0.0,1.4325000047683716,2.0874000042676926,2.5560666769742966,-8.551487719445994,-31.37395794578791,-18.335463504472454,29.0123898867395,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-06,1.315000057220459,1.4850000143051147,1.2999999523162842,1.3200000524520874,56605,0.0,0.0,1.4045000076293945,2.0670250058174133,2.5566500107447307,-6.016372710451714,-32.052103691218804,-19.151037602706275,29.51156932215133,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-07,1.340000033378601,1.4600000381469727,1.284999966621399,1.3300000429153442,68127,0.0,0.0,1.3785000085830688,2.045400008559227,2.5577333440383274,-3.5183144987845605,-32.604869325580985,-20.030756398952555,30.041348719017776,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-08,1.2899999618530273,1.3250000476837158,1.2799999713897705,1.309999942779541,13222,0.0,0.0,1.3649999976158143,2.0220250099897386,2.5579333434502285,-4.02930805365124,-32.49341670493278,-20.95083262559291,29.562784929866012,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-10,1.309999942779541,1.399999976158142,1.2799999713897705,1.3550000190734863,87470,0.0,0.0,1.3615000009536744,1.9995250076055526,2.558925010760625,-0.47741328502644936,-31.90882855803431,-21.86074233526657,32.18060667922511,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-13,1.5,1.5,1.2899999618530273,1.3899999856948853,138249,0.0,0.0,1.3554999947547912,1.9781500101089478,2.5604416777690253,2.5451856195938283,-31.476380060775256,-22.741844608913038,34.22807646502234,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-14,1.3899999856948853,1.5449999570846558,1.3899999856948853,1.399999976158142,34378,0.0,0.0,1.3454999923706055,1.9615250080823898,2.5621083438396455,4.050537651175631,-31.405412277359527,-23.44098122162957,34.83342450368502,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-15,1.399999976158142,1.4500000476837158,1.350000023841858,1.350000023841858,51255,0.0,0.0,1.340499997138977,1.9426500082015992,2.563408343990644,0.7086927805413445,-30.99631989912893,-24.21613151272907,33.188640956988905,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-16,1.3949999809265137,1.3949999809265137,1.3550000190734863,1.3550000190734863,15503,0.0,0.0,1.3414999961853027,1.9229000091552735,2.5602000107367835,1.0063378998563088,-30.235582204057444,-24.892586474058547,33.52666278530147,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-17,1.350000023841858,1.559999942779541,1.350000023841858,1.4049999713897705,179142,0.0,0.0,1.3524999976158143,1.9064000070095062,2.5577416767676673,3.881698622292282,-29.054763289818318,-25.465498555792028,36.96134125718128,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-20,1.399999976158142,1.399999976158142,1.2000000476837158,1.2200000286102295,220401,0.0,0.0,1.343500006198883,1.8880500078201294,2.551658343275388,-9.192406179294908,-28.841926822158857,-26.006943178898716,30.65079401620156,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-21,1.215000033378601,1.3250000476837158,1.0499999523162842,1.184999942779541,200169,0.0,0.0,1.3299999952316284,1.8726250052452087,2.5461500098307925,-10.902259621950948,-28.97670427841622,-26.452683541231874,29.620425015612824,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-22,0.36083799600601196,0.4230000078678131,0.36083799600601196,0.37599998712539673,706150,0.0,0.0,1.2345999896526336,1.83452500551939,2.534916676580906,-69.5447926229784,-32.70192633307311,-27.629770932202934,16.12621318761164,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-23,0.37599998712539673,0.40783798694610596,0.345676988363266,0.36083799600601196,689984,0.0,0.0,1.1396837949752807,1.7922959566116332,2.5232736597458523,-68.33876224292209,-36.41207576398974,-28.969418370889038,15.97928470426389,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-24,0.33354800939559937,0.33354800939559937,0.24318699538707733,0.26987001299858093,3339969,0.0,0.0,1.0311707943677901,1.7492927066981792,2.5097059098382792,-73.82877652542147,-41.05212978826493,-30.298896781459934,15.090890961915775,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-27,0.2910960018634796,0.2910960018634796,0.17526400089263916,0.2122579962015152,3465348,0.0,0.0,0.9133965954184532,1.7009741570800543,2.4966080594807862,-76.76168301193704,-46.30155951420106,-31.86859464701873,14.539564605908922,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-28,0.2122579962015152,0.22681200504302979,0.19709600508213043,0.2061930000782013,1245434,0.0,0.0,0.7940158978104591,1.6422539804130794,2.483409668132663,-74.03162825243305,-51.6508465023943,-33.8709999607946,14.47959208112573,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-29,0.2061930000782013,0.2061930000782013,0.1855739951133728,0.20134100317955017,606501,0.0,0.0,0.6791499957442284,1.5845375057309865,2.470254176730911,-70.35397122267284,-57.13891319783436,-35.85528482627912,14.42831877400441,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-30,0.20134100317955017,0.22681200504302979,0.1855739951133728,0.2122579962015152,483583,0.0,0.0,0.5648757934570312,1.5313439577817918,2.4571896602710086,-62.42395254671836,-63.112415692992016,-37.67904925935198,15.15630270064365,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-05-31,0.5099999904632568,0.75,0.5099999904632568,0.6000000238418579,290364,0.0,0.0,0.48437579870224,1.4865939557552337,2.448122994105021,23.87076840944638,-67.41707466070231,-39.27617365079735,35.98629891905115,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-03,0.6200000047683716,0.7300000190734863,0.5550000071525574,0.6499999761581421,201805,0.0,0.0,0.42737579345703125,1.4418439537286758,2.440622994303703,52.09096680472,-70.35908134498068,-40.92311851958003,38.096840051682854,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-04,0.6499999761581421,0.6549999713897705,0.5249999761581421,0.6299999952316284,494594,0.0,0.0,0.37187579870223997,1.3925939559936524,2.4331063280502954,69.41139956678597,-73.29617889682015,-42.76477193211814,37.563345700992855,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-05,0.6949999928474426,0.6949999928474426,0.3540000021457672,0.49799999594688416,1570008,0.0,0.0,0.38407579958438876,1.3415439568459988,2.4243063278496266,29.661904365173125,-71.37061386438951,-44.662770482641285,34.162979850699216,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-07,0.49799999594688416,0.5400000214576721,0.3540000021457672,0.4880000054836273,1045954,0.0,0.0,0.39679200053215025,1.2857439562678337,2.415722994506359,22.986351748310234,-69.13911213831952,-46.77601864155087,33.91252362681803,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-10,0.4020000100135803,0.4659999907016754,0.3840000033378601,0.421999990940094,265772,0.0,0.0,0.41200499832630155,1.2302939534187316,2.404956327875455,2.425939649857491,-66.51166193400975,-48.843397314180066,32.23292713496585,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-11,0.41999998688697815,0.41999998688697815,0.37400001287460327,0.38999998569488525,396611,0.0,0.0,0.42977919727563857,1.1727939516305923,2.394439661502838,-9.255732206889704,-63.35424507620493,-51.02010835827436,31.420382879859318,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-12,0.38199999928474426,0.6299999952316284,0.3700000047683716,0.5799999833106995,1123543,0.0,0.0,0.4671598955988884,1.1232939526438712,2.382439661522706,24.154489453156643,-58.41160770968767,-52.85110591527291,40.940178734267974,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-13,0.6000000238418579,0.6200000047683716,0.4020000100135803,0.4860000014305115,780179,0.0,0.0,0.49562579542398455,1.0731939524412155,2.366572993993759,-1.942149517306431,-53.817686514485594,-54.651981782732804,38.12079985837769,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-14,0.48399999737739563,0.48399999737739563,0.3959999978542328,0.42800000309944153,497050,0.0,0.0,0.5171999961137772,1.0213939525187015,2.3492229940990605,-17.246711849300333,-49.36331913475791,-56.522051968488775,36.45271374521039,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-17,0.4259999990463257,0.4259999990463257,0.3540000021457672,0.39800000190734863,210701,0.0,0.0,0.49699999392032623,0.9708439506590366,2.3317479950686297,-19.919515739239273,-48.807427436412574,-58.36411341567543,35.58534139585642,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-18,0.39399999380111694,0.4300000071525574,0.3799999952316284,0.41200000047683716,370123,0.0,0.0,0.47319999635219573,0.9191439501941204,2.3038896607855954,-12.933219853579272,-48.51731371867733,-60.10468878615026,36.34652465990803,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-19,0.41200000047683716,0.41600000858306885,0.3179999887943268,0.3880000114440918,187379,0.0,0.0,0.4489999979734421,0.8888439498841763,2.2713729945321877,-13.58574316362433,-49.48494636972547,-60.86754786537194,35.5705232492934,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-20,0.3880000114440918,0.414000004529953,0.3799999952316284,0.3919999897480011,102693,0.0,0.0,0.4383999973535538,0.8588939487934113,2.242097994685173,-10.58394340457369,-48.957610195132304,-61.692399224771,35.81647756250656,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-24,0.38999998569488525,0.41999998688697815,0.3720000088214874,0.4180000126361847,202372,0.0,0.0,0.4313999980688095,0.8332189477980136,2.213956327488025,-3.106162608393775,-48.22489344380726,-62.365158813074174,37.48695745877572,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-25,0.4180000126361847,0.41999998688697815,0.37400001287460327,0.38199999928474426,315674,0.0,0.0,0.4273999989032745,0.8080189481377602,2.1838479951024055,-10.622367743338433,-47.105200950014535,-63.00022025572021,36.08648087236211,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-26,0.38199999928474426,0.38199999928474426,0.25,0.28999999165534973,944172,0.0,0.0,0.417399999499321,0.779018946737051,2.1551813282072545,-30.522282701674637,-46.419788472717386,-63.853670383036274,32.72208906683217,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-27,0.2879999876022339,0.3199999928474426,0.27000001072883606,0.3059999942779541,336556,0.0,0.0,0.39000000059604645,0.7491689465939999,2.127397993952036,-21.53846312556746,-47.942316300064064,-64.78473004469278,33.87669415332006,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-06-28,0.3199999928474426,0.3199999928474426,0.2800000011920929,0.28999999165534973,125177,0.0,0.0,0.37039999961853026,0.72141894698143,2.098189659913381,-21.706265671161816,-48.65674083438445,-65.6170764366834,33.26195145707315,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-01,0.2919999957084656,0.30000001192092896,0.2800000011920929,0.28999999165534973,79637,0.0,0.0,0.3565999984741211,0.695043946057558,2.06510632460316,-18.67639010200518,-48.69389187592603,-66.34343046762395,33.26195145707315,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-02,0.30000001192092896,0.30000001192092896,0.23000000417232513,0.25999999046325684,288746,0.0,0.0,0.3427999973297119,0.6691689468920231,2.0339396578570206,-24.154027862146204,-48.77227956828278,-67.09986236282613,31.999244246222972,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-03,0.25999999046325684,0.2800000011920929,0.25999999046325684,0.2680000066757202,144908,0.0,0.0,0.32839999794960023,0.6431189484894275,2.00250632489721,-18.392202086173473,-48.93635170897178,-67.88429876632527,32.7325985830403,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-04,0.2680000066757202,0.2680000066757202,0.20000000298023224,0.2199999988079071,381715,0.0,0.0,0.31159999668598176,0.6156189471483231,1.9685063232978186,-29.396662019347048,-49.38427445591486,-68.72659539558994,30.600240715681053,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-05,0.2199999988079071,0.23800000548362732,0.19200000166893005,0.21199999749660492,349799,0.0,0.0,0.29359999746084214,0.5876689460128546,1.9349396585176388,-27.79291575951745,-50.03989925742648,-69.62856472418014,30.24657799119464,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-08,0.21199999749660492,0.23999999463558197,0.19099999964237213,0.21799999475479126,367581,0.0,0.0,0.27359999567270277,0.5603689473122359,1.9030063235511383,-20.321638083804526,-51.17502549257896,-70.5534900027789,30.891697754101855,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-09,0.23000000417232513,0.24400000274181366,0.18000000715255737,0.20800000429153442,486547,0.0,0.0,0.2561999961733818,0.531693946942687,1.8696563232690095,-18.813424122468884,-51.81438539096281,-71.56194214276536,30.387269135989,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-10,0.19499999284744263,0.2199999988079071,0.18000000715255737,0.20800000429153442,333901,0.0,0.0,0.24799999743700027,0.5021439474076033,1.836431321874261,-16.129029660827754,-50.61177203920527,-72.65653545403946,30.387269135989,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-11,0.21199999749660492,0.2199999988079071,0.19099999964237213,0.20999999344348907,231516,0.0,0.0,0.23839999735355377,0.4723939478397369,1.80484798848629,-11.912753450222027,-49.53364698177025,-73.82638588660701,30.649934155543633,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-12,0.2199999988079071,0.23800000548362732,0.2199999988079071,0.23600000143051147,406871,0.0,0.0,0.23299999833106994,0.4445439472794533,1.7698146546880404,1.287554987523576,-47.58673472960383,-74.88189251332584,34.1295760538695,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-15,0.9150000214576721,0.9150000214576721,0.3580000102519989,0.4359999895095825,3161613,0.0,0.0,0.24759999811649322,0.4215689465403557,1.7343646541237832,76.0904656002659,-41.26702164653128,-75.69317700646198,53.469871289021974,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-16,0.44600000977516174,0.4580000042915344,0.4059999883174896,0.4099999964237213,1105881,0.0,0.0,0.2625999987125397,0.39669394716620443,1.6969479866325856,56.130997118753214,-33.802872317959235,-76.62309332453955,51.358741377622124,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-17,0.19699999690055847,0.23600000143051147,0.16899999976158142,0.17399999499320984,13538285,0.0,0.0,0.2531999975442886,0.370543946325779,1.6610229854782423,-31.27962216398737,-31.668024790323408,-77.69182307738555,37.05674780014375,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-18,0.17800000309944153,0.17900000512599945,0.16099999845027924,0.16899999976158142,3360342,0.0,0.0,0.24809999763965607,0.34514394775032997,1.6240979862709841,-31.88230497001479,-28.11694967946345,-78.74857609159415,36.82278805335718,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-19,0.16899999976158142,0.18000000715255737,0.1599999964237213,0.1720000058412552,2034364,0.0,0.0,0.2440999984741211,0.3400439482182264,1.5872813183814287,-29.537072135831977,-28.21516167155323,-78.57695770243338,37.07947477784852,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-22,0.1720000058412552,0.17900000512599945,0.16200000047683716,0.17000000178813934,2340285,0.0,0.0,0.2392999991774559,0.33527299836277963,1.5522396517296633,-28.959464115136196,-28.625329106126486,-78.40069360493501,36.97162855052519,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-23,0.17000000178813934,0.17499999701976776,0.16300000250339508,0.17000000178813934,867553,0.0,0.0,0.2354999989271164,0.3327762480825186,1.5211563176165024,-27.813162393791895,-29.231728440931455,-78.1234680335848,36.97162855052519,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-24,0.17100000381469727,0.17499999701976776,0.17000000178813934,0.17299999296665192,359105,0.0,0.0,0.23199999779462815,0.331794798001647,1.4910979844629764,-25.43103680552809,-30.077264866136776,-77.74829008831745,37.288931458911186,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-25,0.17399999499320984,0.17399999499320984,0.16699999570846558,0.17000000178813934,522064,0.0,0.0,0.22799999862909318,0.33088997304439544,1.4597646505882342,-25.4385952586374,-31.09492060718852,-77.33264927938498,37.08785815975825,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-26,0.17000000178813934,0.17299999296665192,0.16500000655651093,0.1679999977350235,1130342,0.0,0.0,0.22119999825954437,0.33005644790828226,1.4292063169181346,-24.05063333775383,-32.981161355462284,-76.9063119858021,36.944829288649956,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-29,0.17000000178813934,0.17800000309944153,0.17000000178813934,0.17299999296665192,397369,0.0,0.0,0.1948999986052513,0.3290749978274107,1.3998146497954924,-11.236534528127661,-40.77337996140621,-76.4915306554702,37.5927921397122,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-30,0.17000000178813934,0.17499999701976776,0.17000000178813934,0.17399999499320984,298675,0.0,0.0,0.17129999846220018,0.3184249971061945,1.3737646501511336,1.5761801256556673,-46.20397267207267,-76.82099353254117,37.73061458610993,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-07-31,0.17399999499320984,0.17800000309944153,0.16599999368190765,0.17100000381469727,299112,0.0,0.0,0.1709999993443489,0.3064499977976084,1.3468563160548608,2.6142388224542764e-06,-44.199706127169236,-77.24701631906474,37.46331689401353,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-01,0.17000000178813934,0.1770000010728836,0.16300000250339508,0.16699999570846558,697229,0.0,0.0,0.17079999893903733,0.2948749978095293,1.3220813151448965,-2.2248262612273586,-42.07715126483413,-77.6961526926041,37.08605964012431,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-02,0.17299999296665192,0.17299999296665192,0.15399999916553497,0.16200000047683716,633094,0.0,0.0,0.16979999840259552,0.28647499792277814,1.2988479814181726,-4.593638397607389,-40.727812327843495,-77.94391629958228,36.59005263565474,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-05,0.1679999977350235,0.17000000178813934,0.14499999582767487,0.15800000727176666,555145,0.0,0.0,0.16859999895095826,0.2782249979674816,1.2757479809224606,-6.287065092019889,-39.40156341715065,-78.19122568657296,36.17324189987756,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-06,0.15800000727176666,0.17000000178813934,0.1509999930858612,0.16099999845027924,695857,0.0,0.0,0.16769999861717225,0.27169999815523627,1.2569646478941043,-3.9952297090877495,-38.277512051598706,-78.38443598151805,36.75513942392133,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-07,0.16099999845027924,0.17000000178813934,0.16099999845027924,0.16899999976158142,242560,0.0,0.0,0.1672999992966652,0.2661749985069036,1.2396646488457919,1.0161389552080589,-37.146613981355564,-78.52846745652303,38.36875264805705,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-08,0.16899999976158142,0.16899999976158142,0.1599999964237213,0.1679999977350235,163635,0.0,0.0,0.1670999988913536,0.25587499886751175,1.2229813148578008,0.5385989525081119,-34.69467527858183,-79.0777671123076,38.23742434249042,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-09,0.1679999977350235,0.17000000178813934,0.1599999964237213,0.16899999976158142,309604,0.0,0.0,0.1671999990940094,0.2479499988257885,1.206472980727752,1.0765554290224357,-32.5670498544808,-79.44835874598505,38.464250345155406,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-12,0.16899999976158142,0.17100000381469727,0.15399999916553497,0.1599999964237213,933530,0.0,0.0,0.16589999943971634,0.2412499986588955,1.1894729803005855,-3.556361082532089,-31.23316047172994,-79.71790846413927,37.14216018528782,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-13,0.1599999964237213,0.1679999977350235,0.1550000011920929,0.1589999943971634,656617,0.0,0.0,0.16439999938011168,0.23527499847114086,1.1732979810486237,-3.284674576222388,-30.124322410620607,-79.94754936330274,36.99002442425948,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-14,0.1589999943971634,0.16899999976158142,0.1550000011920929,0.16200000047683716,239252,0.0,0.0,0.16349999904632567,0.22902499847114086,1.1563563149422407,-0.9174303230812305,-28.610413650137804,-80.19425366457392,37.81296774036852,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-15,0.16099999845027924,0.16899999976158142,0.15600000321865082,0.16099999845027924,507038,0.0,0.0,0.16289999932050706,0.22334999814629555,1.1372396488984426,-1.1663602689706292,-27.065144091110938,-80.36034020070989,37.636512963928574,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-16,0.16899999976158142,0.16899999976158142,0.1550000011920929,0.15800000727176666,555942,0.0,0.0,0.1625,0.21749999858438968,1.1152646483232578,-2.7692262942974417,-25.28735583556786,-80.49790254614547,37.07751902124439,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-19,0.15800000727176666,0.17900000512599945,0.15800000727176666,0.17900000512599945,1437454,0.0,0.0,0.16459999978542328,0.21152499839663505,1.0945479820171993,8.748484422447378,-22.184138502259533,-80.67467101745464,43.41324608798025,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-20,0.1770000010728836,0.17800000309944153,0.1599999964237213,0.16899999976158142,1672530,0.0,0.0,0.1653999999165535,0.206199998408556,1.0751646496355534,2.1765416244523443,-19.78661435833918,-80.82154221881726,41.281610697277955,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-21,0.17399999499320984,0.17399999499320984,0.1550000011920929,0.1599999964237213,572125,0.0,0.0,0.16449999958276748,0.20294999852776527,1.0557896504799524,-2.7355642373615994,-18.94555270949534,-80.77742110509361,39.406257909771085,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-22,0.1599999964237213,0.1770000010728836,0.1599999964237213,0.16599999368190765,481060,0.0,0.0,0.1642999991774559,0.1994499985128641,1.038256317252914,1.034689295777551,-17.62346432564204,-80.78990754030933,41.320111405823816,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-23,0.17599999904632568,0.17599999904632568,0.15600000321865082,0.16200000047683716,909591,0.0,0.0,0.16359999924898147,0.1962499987334013,1.0206063174953064,-0.9779943639909725,-16.636942519818152,-80.77123418018586,40.40389712358468,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-26,0.16099999845027924,0.164000004529953,0.1469999998807907,0.15700000524520874,1666383,0.0,0.0,0.16330000013113022,0.19292499907314778,1.0040396510312954,-3.8579270550291302,-15.355707702134133,-80.78512149644831,39.23283408142932,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-27,0.15600000321865082,0.15800000727176666,0.15000000596046448,0.1550000011920929,754111,0.0,0.0,0.16290000081062317,0.19029999934136868,0.9875396511207024,-4.849600723890906,-14.398317722321252,-80.7298877442128,38.749036276860934,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-28,0.15700000524520874,0.15700000524520874,0.14800000190734863,0.1550000011920929,929989,0.0,0.0,0.16220000088214875,0.187474999204278,0.9726646506537994,-4.438964026447344,-13.481796735248357,-80.72562839841436,38.749036276860934,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-29,0.1469999998807907,0.17000000178813934,0.1469999998807907,0.1599999964237213,946977,0.0,0.0,0.16210000067949296,0.18597499914467336,0.9562063173701366,-1.2954992270011205,-12.837746242766537,-80.55074561145315,40.863395043302106,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-08-30,0.1469999998807907,0.1599999964237213,0.1469999998807907,0.15299999713897705,282325,0.0,0.0,0.161599999666214,0.18449999913573265,0.9391896512359381,-5.3217837530942536,-12.411923889859542,-80.35540543989836,38.84187067342495,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-02,0.15299999713897705,0.15299999713897705,0.14399999380111694,0.14900000393390656,1072593,0.0,0.0,0.1585999995470047,0.18277499936521052,0.9217229855557283,-6.052960681284857,-13.22664472830921,-80.17028953064339,37.69433405905704,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-03,0.15399999916553497,0.15399999916553497,0.1459999978542328,0.15199999511241913,527908,0.0,0.0,0.15689999908208846,0.18137499913573266,0.9041979845613242,-3.1230108338660343,-13.494142064931584,-79.94078705851932,39.14643839580496,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-04,0.1589999943971634,0.1589999943971634,0.1420000046491623,0.1459999978542328,240800,0.0,0.0,0.15549999922513963,0.17982499897480012,0.8867063188304504,-6.109325670897483,-13.52704011585691,-79.71989201430458,37.275294770620675,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-05,0.14499999582767487,0.14499999582767487,0.13099999725818634,0.14399999380111694,506082,0.0,0.0,0.15329999923706056,0.1781749989837408,0.8706979849686225,-6.066539779665779,-13.960993342814723,-79.5365325222199,36.646495789899575,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-06,0.1469999998807907,0.16500000655651093,0.14300000667572021,0.1509999930858612,275799,0.0,0.0,0.15219999849796295,0.17604999877512456,0.8544146514187256,-0.7884398317637346,-13.547287954046586,-79.39525048139102,40.4339004461408,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-09,0.1509999930858612,0.15600000321865082,0.13500000536441803,0.15000000596046448,117604,0.0,0.0,0.15149999856948854,0.1688999991863966,0.8377896516273419,-0.9900941407178013,-10.301954233703436,-79.83980837453394,40.06541376445351,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-10,0.15000000596046448,0.15299999713897705,0.1469999998807907,0.1469999998807907,76404,0.0,0.0,0.1506999984383583,0.16232499927282334,0.821806317816178,-2.4552080928395084,-7.16155914772354,-80.24777909907328,38.91949004502248,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-11,0.1469999998807907,0.1550000011920929,0.1420000046491623,0.1469999998807907,260972,0.0,0.0,0.14989999830722808,0.16164999939501284,0.8067479845136404,-1.9346220541601808,-7.26879129709868,-79.96276377529895,38.91949004502248,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-12,0.1469999998807907,0.14900000393390656,0.1379999965429306,0.14100000262260437,1022639,0.0,0.0,0.1479999989271164,0.16094999946653843,0.7929063174873591,-4.729727267065205,-8.045977373311104,-79.70125903693479,36.49815299207575,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-13,0.14100000262260437,0.14300000667572021,0.12399999797344208,0.1289999932050705,1551441,0.0,0.0,0.14559999853372574,0.1598749991506338,0.7781479842960835,-11.401102675705136,-8.928851097886916,-79.45442224652712,32.185333000287415,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-16,0.13699999451637268,0.13699999451637268,0.12200000137090683,0.12999999523162842,533562,0.0,0.0,0.14369999766349792,0.15887499898672103,0.7621479846537114,-9.533752717206562,-9.551535118808374,-79.15431094934833,32.89693438207448,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-17,0.12999999523162842,0.13500000536441803,0.12200000137090683,0.12800000607967377,759300,0.0,0.0,0.1412999987602234,0.1578249990940094,0.7466313179582358,-9.412592213195147,-10.470458057118567,-78.86172260686799,32.16986831581413,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-18,0.12600000202655792,0.15000000596046448,0.12600000202655792,0.13699999451637268,743186,0.0,0.0,0.14039999842643738,0.15692499913275243,0.7298979847381513,-2.4216552337400032,-10.530508712850487,-78.50042027598573,38.7320846776232,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-19,0.13500000536441803,0.14900000393390656,0.13500000536441803,0.14399999380111694,412702,0.0,0.0,0.14039999842643738,0.15627499893307686,0.7098063174635172,2.56409929845247,-10.158375053605205,-77.98343081933628,43.32472318329661,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-20,0.14399999380111694,0.15000000596046448,0.13500000536441803,0.1459999978542328,195841,0.0,0.0,0.13989999890327454,0.1557249989360571,0.6901063175251086,4.360256610992349,-10.162144897031292,-77.43463652172822,44.60244790396611,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-23,0.14900000393390656,0.14900000393390656,0.13300000131130219,0.14300000667572021,579023,0.0,0.0,0.13919999897480012,0.1549749992787838,0.6717979849626621,2.7298906098469318,-10.179061382414403,-76.93130930016154,43.03518760243336,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-24,0.14100000262260437,0.14100000262260437,0.13500000536441803,0.14000000059604645,198320,0.0,0.0,0.13849999904632568,0.1541249994188547,0.6530479840934277,1.0830336173641757,-10.137875381310508,-76.39913097154512,41.46604681041743,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-25,0.14000000059604645,0.15000000596046448,0.13600000739097595,0.14499999582767487,223678,0.0,0.0,0.1382999986410141,0.15347499921917915,0.6339229835818211,4.844538866592448,-9.887604271294682,-75.78964587275135,45.061449567225964,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-26,0.14800000190734863,0.1599999964237213,0.13899999856948853,0.15000000596046448,388481,0.0,0.0,0.13919999897480012,0.15304999947547912,0.6135063177595536,7.7586257652340365,-9.049330642368265,-75.05323171986262,48.470118427766906,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-27,0.15000000596046448,0.15600000321865082,0.1420000046491623,0.15299999713897705,150121,0.0,0.0,0.14159999936819076,0.15282499939203262,0.5936146513869365,8.05084591924596,-7.345002498607609,-74.25518406006853,50.45634785199177,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-09-30,0.15299999713897705,0.15299999713897705,0.1420000046491623,0.1469999998807907,544104,0.0,0.0,0.14329999983310698,0.15254999920725823,0.5721729844808578,2.581995849262315,-6.063585330855339,-73.3384827062974,46.588538071668474,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-01,0.14900000393390656,0.15800000727176666,0.13500000536441803,0.1469999998807907,1108623,0.0,0.0,0.1451999992132187,0.15219999924302102,0.551397983605663,1.239669887965229,-4.599211606187516,-72.39743274943345,46.588538071668474,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-02,0.14499999582767487,0.14499999582767487,0.13699999451637268,0.14300000667572021,173976,0.0,0.0,0.14580000042915345,0.1515499994158745,0.5301729831844568,-1.9204346674839654,-3.794126696722868,-71.41499015932551,43.98178601531185,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-03,0.13699999451637268,0.13899999856948853,0.13500000536441803,0.13899999856948853,83974,0.0,0.0,0.1453000009059906,0.1508249994367361,0.5099979836493731,-4.335858428919205,-3.663184850905953,-70.4263537754633,41.482196535572555,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-04,0.1379999965429306,0.13899999856948853,0.12999999523162842,0.13600000739097595,334961,0.0,0.0,0.1443000018596649,0.14999999962747096,0.490381316964825,-5.751901844575783,-3.799998521308101,-69.41155903820243,39.661615492238084,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-07,0.13500000536441803,0.13899999856948853,0.1340000033378601,0.1379999965429306,551193,0.0,0.0,0.14380000084638594,0.1494499996304512,0.4706979836026827,-4.0333826629467024,-3.7805278006263916,-68.24927982767773,41.50476723312261,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-08,0.1379999965429306,0.1379999965429306,0.1340000033378601,0.13500000536441803,263694,0.0,0.0,0.14330000132322313,0.14884999990463257,0.4516563163449367,-5.792041787971709,-3.728584874010953,-67.04352523856798,39.55301781551742,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-09,0.13500000536441803,0.13899999856948853,0.13099999725818634,0.13899999856948853,62356,0.0,0.0,0.14270000159740448,0.14827499985694886,0.4321479828407367,-2.592854230201531,-3.7599044106713673,-65.68883675396121,43.37639835321191,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-10,0.13899999856948853,0.13899999856948853,0.13099999725818634,0.13600000739097595,60862,0.0,0.0,0.14130000174045562,0.14765000008046628,0.41994798270364603,-3.750880597450289,-4.300710014595349,-64.84088359470421,41.26809670364887,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-11,0.13500000536441803,0.13500000536441803,0.1289999932050705,0.1340000033378601,213046,0.0,0.0,0.13940000236034394,0.1470499999821186,0.40781464911997317,-3.873743852977158,-5.202310522070654,-63.941952477813366,39.87656662013801,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-14,0.14399999380111694,0.14399999380111694,0.12999999523162842,0.13199999928474426,158641,0.0,0.0,0.1379000023007393,0.14587499983608723,0.39687298201024535,-4.278464769803268,-5.4670077424569445,-63.24390763583866,38.47926671097998,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-15,0.14100000262260437,0.14100000262260437,0.12999999523162842,0.13300000131130219,140184,0.0,0.0,0.13650000244379043,0.14497499987483026,0.3863979821403821,-2.5641033478585586,-5.845833721922429,-62.48039415947068,39.61854580545338,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-16,0.13300000131130219,0.14000000059604645,0.12999999523162842,0.14000000059604645,230882,0.0,0.0,0.13620000183582306,0.14447499997913837,0.3754813150813182,2.7900137364197266,-5.727633254549359,-61.522719193670305,47.01529576765982,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-17,0.14000000059604645,0.14000000059604645,0.13099999725818634,0.13300000131130219,180036,0.0,0.0,0.13560000211000442,0.14365000016987323,0.36408964842557906,-1.917404688971173,-5.603897006856448,-60.545431381789015,41.535754999025684,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-18,0.12999999523162842,0.13899999856948853,0.12999999523162842,0.12999999523162842,137127,0.0,0.0,0.13500000089406966,0.142850000038743,0.35350631525119147,-3.7037078735759366,-5.4952741634891975,-59.59053802554054,39.41553355642993,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-21,0.12999999523162842,0.13199999928474426,0.1289999932050705,0.12999999523162842,58704,0.0,0.0,0.13420000076293945,0.1421749997884035,0.3433813149730364,-3.1296613319177413,-5.60928365558861,-58.59559225010027,39.41553355642993,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-22,0.12999999523162842,0.12999999523162842,0.125,0.12700000405311584,279758,0.0,0.0,0.13340000063180923,0.1414749998599291,0.33364798203110696,-4.797598611980299,-5.707721672461363,-57.59752569199146,37.212528456030824,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-23,0.12700000405311584,0.12999999523162842,0.12200000137090683,0.12399999797344208,179756,0.0,0.0,0.13190000057220458,0.14069999977946282,0.3237646491577228,-5.98938784267699,-6.254441521714009,-56.54250698910601,35.099818843426945,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-24,0.12399999797344208,0.13199999928474426,0.11599999666213989,0.12200000137090683,207613,0.0,0.0,0.13049999997019768,0.13974999990314246,0.31378131539871296,-6.513408889832946,-6.6189623895211085,-55.462612639772345,33.72515536677871,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-25,0.13099999725818634,0.13300000131130219,0.11800000071525574,0.125,258005,0.0,0.0,0.12959999963641167,0.13904999997466802,0.3037396483744184,-3.549382445460499,-6.7961167493548675,-54.2206620970135,37.668592610389034,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-28,0.11800000071525574,0.12999999523162842,0.11800000071525574,0.125,419621,0.0,0.0,0.12889999970793725,0.13844999987632037,0.29386464885125557,-3.025601021546862,-6.897797166424187,-52.886473273483425,37.66859261038902,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-29,0.11999999731779099,0.12800000607967377,0.11500000208616257,0.11900000274181366,1513218,0.0,0.0,0.1274999998509884,0.13762500006705522,0.2835646487151583,-6.666664407144187,-7.356948382295084,-51.46609399632885,33.100266778865134,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-30,0.125,0.125,0.11800000071525574,0.12099999934434891,129852,0.0,0.0,0.12559999972581865,0.13700000010430813,0.2729896488289038,-3.6624206938785133,-8.321168153145859,-49.81494694321804,35.89125400646594,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-10-31,0.12099999934434891,0.12300000339746475,0.11500000208616257,0.11800000071525574,439734,0.0,0.0,0.12409999966621399,0.1363500002771616,0.2623063157002131,-4.915389981760787,-8.984232186319595,-48.01878867720652,33.625177685148685,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-01,0.11800000071525574,0.11800000071525574,0.09799999743700027,0.10000000149011612,1941916,0.0,0.0,0.12110000029206276,0.13507500048726798,0.25188964884728193,-17.42361581425165,-10.346104123481,-46.37532701109027,23.882126115204258,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-04,0.10000000149011612,0.10000000149011612,0.08349999785423279,0.08699999749660492,2112455,0.0,0.0,0.1168000005185604,0.1335000002756715,0.24132298200080793,-25.513701104153707,-12.509363088109618,-44.67994752558438,19.489809070802238,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-05,0.10000000149011612,0.10000000149011612,0.08349999785423279,0.08699999749660492,743170,0.0,0.0,0.11279999986290931,0.13200000021606684,0.23033964888503153,-22.872342551117235,-14.545454789189108,-42.69332229383077,19.489809070802238,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-06,0.09000000357627869,0.09350000321865082,0.08299999684095383,0.08950000256299973,902302,0.0,0.0,0.10935000032186508,0.13056250028312205,0.22091881533463795,-18.15271851891915,-16.24700807295978,-40.90023519031106,22.66214791639544,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-07,0.09000000357627869,0.09749999642372131,0.07349999994039536,0.07999999821186066,950663,0.0,0.0,0.10515000000596046,0.12903750017285348,0.21171048246324062,-23.91821378285703,-18.51206055208314,-39.05001836871336,19.515326276281826,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-08,0.08950000256299973,0.08950000256299973,0.07100000232458115,0.07249999791383743,2899811,0.0,0.0,0.09989999979734421,0.12762500029057264,0.20918131588647762,-27.427429368458505,-21.72380053289325,-38.98833662570775,17.45467295267487,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-11,0.07450000196695328,0.08049999922513962,0.06599999964237213,0.0689999982714653,4202540,0.0,0.0,0.09429999962449073,0.12610000036656857,0.20674933257202308,-26.82926983432855,-25.21808140335946,-39.00826725878767,16.575090747117144,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-12,0.0689999982714653,0.07850000262260437,0.06599999964237213,0.06750000268220901,646272,0.0,0.0,0.08914999961853028,0.12458750028163194,0.20506291581938665,-24.284909735233697,-28.443865221627096,-39.244255947591746,16.198350366070656,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-13,0.07800000160932541,0.07999999821186066,0.06499999761581421,0.07100000232458115,2227672,0.0,0.0,0.0841499999165535,0.12293750047683716,0.20388576587041218,-15.62685395723401,-31.55058498004168,-39.70275465184997,20.726068239648598,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-14,0.07150000333786011,0.08399999886751175,0.07050000131130219,0.08150000125169754,998506,0.0,0.0,0.08049999997019767,0.12137500066310167,0.202846657546858,1.2422376172299143,-33.67662242602986,-40.16416039043493,32.50727299298396,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-15,0.08299999684095383,0.08399999886751175,0.07699999958276749,0.0794999971985817,721529,0.0,0.0,0.07844999954104423,0.11971250064671039,0.2018313158303499,1.3384291442705718,-34.467996978392435,-40.68685518191082,31.545606484513584,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-18,0.08500000089406967,0.08799999952316284,0.07249999791383743,0.08250000327825546,154445,0.0,0.0,0.0780000001192093,0.11820000056177378,0.2007499992226561,5.769234810472697,-34.01015249704261,-41.12079650337849,34.66771328086925,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-19,0.08250000327825546,0.08250000327825546,0.0729999989271164,0.0794999971985817,431724,0.0,0.0,0.07725000008940697,0.11668750047683715,0.1964124990006288,2.9126176136836834,-33.79753634817009,-40.590593230798625,33.04466134727494,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-20,0.07999999821186066,0.07999999821186066,0.07349999994039536,0.07699999958276749,451223,0.0,0.0,0.07599999979138375,0.11498750057071447,0.191637499195834,1.315789202800905,-33.905859842004624,-39.99739035771441,31.712255602292288,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-21,0.07900000363588333,0.07999999821186066,0.07249999791383743,0.0754999965429306,527924,0.0,0.0,0.07554999962449074,0.11312500033527613,0.1870166658734282,-0.06618541602736308,-33.215470143135335,-39.5107383574903,30.907008102231245,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-22,0.0729999989271164,0.0729999989271164,0.06949999928474426,0.07249999791383743,605912,0.0,0.0,0.07554999962449074,0.11111250035464763,0.18347083255648614,-4.037063832975326,-32.00585048185299,-39.438602416305685,29.304325291700522,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-25,0.07699999958276749,0.07699999958276749,0.06949999928474426,0.07249999791383743,542849,0.0,0.0,0.07589999958872795,0.1092500003054738,0.18000833249340456,-4.479580623601819,-30.526316360179358,-39.30836490056554,29.304325291700522,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-26,0.07000000029802322,0.07199999690055847,0.06949999928474426,0.07000000029802322,411112,0.0,0.0,0.07614999935030937,0.10732500031590461,0.17707499923805395,-8.076164287270169,-29.047287094184504,-39.39008850615872,27.90579181086663,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-27,0.07199999690055847,0.0754999965429306,0.06949999928474426,0.07000000029802322,663322,0.0,0.0,0.07604999914765358,0.10550000015646219,0.17440833269308012,-7.9552911471886825,-27.91469285794566,-39.50977081919662,27.90579181086663,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-28,0.07349999994039536,0.07400000095367432,0.06949999928474426,0.07100000232458115,180331,0.0,0.0,0.07499999925494194,0.1038000002503395,0.17016666618486245,-5.333329293462925,-27.745665631926013,-39.00097911210459,29.467363446874586,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-11-29,0.07000000029802322,0.07500000298023224,0.06949999928474426,0.07500000298023224,458667,0.0,0.0,0.07454999983310699,0.10227500014007092,0.1667416661977768,0.603625953229586,-27.10828674553224,-38.66260157268683,35.48677647861052,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-02,0.07500000298023224,0.07500000298023224,0.07100000232458115,0.07349999994039536,423729,0.0,0.0,0.07364999949932098,0.10066250022500753,0.16378749950478474,-0.20366539028558828,-26.83472064105939,-38.540791861794766,34.30446623565379,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-03,0.09600000083446503,0.09600000083446503,0.07599999755620956,0.07649999856948853,2771015,0.0,0.0,0.07334999963641167,0.0992000000551343,0.16110833281030257,4.294477094330021,-26.058468149551885,-38.42652436113432,38.70309252718679,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-04,0.07649999856948853,0.0794999971985817,0.07100000232458115,0.0794999971985817,356462,0.0,0.0,0.07359999939799308,0.09771250002086163,0.15833749944965045,8.016301425064269,-24.676986688213404,-38.28846586532516,42.82565372435039,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-05,0.07999999821186066,0.08550000190734863,0.07000000029802322,0.08449999988079071,768995,0.0,0.0,0.07449999973177909,0.096424999833107,0.15580833268662295,13.422819040287818,-22.737879325149947,-38.11306611755711,48.98405959917236,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-06,0.08399999886751175,0.08399999886751175,0.07150000333786011,0.07999999821186066,545366,0.0,0.0,0.07524999976158142,0.095074999704957,0.1532083327571551,6.3122903193739655,-20.851958984904368,-37.94397602664543,44.35360967839466,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-09,0.07999999821186066,0.0949999988079071,0.07999999821186066,0.08349999785423279,1095120,0.0,0.0,0.07634999975562096,0.09386249966919422,0.15042083263397216,9.364765057625874,-18.657610840637865,-37.6000664099531,48.43635278023692,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-10,0.08349999785423279,0.09799999743700027,0.07649999856948853,0.08049999922513962,1045769,0.0,0.0,0.07739999964833259,0.09254999961704016,0.14790833263347547,4.005167430092885,-16.36953001771615,-37.4274606648539,45.36404600988888,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-11,0.07599999755620956,0.08550000190734863,0.07500000298023224,0.07750000059604645,1658648,0.0,0.0,0.07814999967813492,0.09098749961704015,0.14613749937464793,-0.8317326740441846,-14.109080909946254,-37.73843126754313,42.463413373519515,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-12,0.07500000298023224,0.09700000286102295,0.07500000298023224,0.08749999850988388,1318231,0.0,0.0,0.07979999929666519,0.0898499995470047,0.1443166660765807,9.649121906120708,-11.18530918309231,-37.74107870581878,53.20450716481911,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-13,0.09449999779462814,0.09449999779462814,0.08950000256299973,0.08950000256299973,295116,0.0,0.0,0.08124999925494195,0.08883749973028898,0.14264583283414442,10.153850318412134,-8.540875754476115,-37.7216298820442,55.01336155132253,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-16,0.09000000357627869,0.09000000357627869,0.08049999922513962,0.08500000089406967,791917,0.0,0.0,0.08239999935030937,0.08771249987185001,0.14093749957780044,3.155341704199351,-6.056719999204592,-37.76496664506888,50.30195155604913,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-17,0.08500000089406967,0.08950000256299973,0.07850000262260437,0.0885000005364418,177574,0.0,0.0,0.0835999995470047,0.08674999978393316,0.13950833299507698,5.861245234435728,-3.6311242014687246,-37.81733469140196,53.62835718167957,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-18,0.08900000154972076,0.08900000154972076,0.07800000160932541,0.08250000327825546,1480845,0.0,0.0,0.08390000015497208,0.0857124999165535,0.13796249963343143,-1.668649432813678,-2.1146271119685,-37.872610206184305,47.73043547103378,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-19,0.07800000160932541,0.08649999648332596,0.07800000160932541,0.0820000022649765,124909,0.0,0.0,0.08365000039339066,0.08471249993890524,0.13681249966224035,-1.9725022362875249,-1.2542417545000588,-38.08131556104773,47.263949023255044,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-20,0.07999999821186066,0.08699999749660492,0.0754999965429306,0.08150000125169754,916927,0.0,0.0,0.08380000069737434,0.08362499997019768,0.13572499969353277,-2.7446293872750083,0.2092684331707355,-38.38644305837315,46.77167015192681,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-23,0.08150000125169754,0.08649999648332596,0.06949999928474426,0.07750000059604645,1091388,0.0,0.0,0.08320000097155571,0.08243749998509883,0.13455416640887657,-6.850961909793687,0.9249443355204868,-38.73285221463019,42.920279321676674,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-27,0.06949999928474426,0.08349999785423279,0.06949999928474426,0.07750000059604645,1188861,0.0,0.0,0.0829000011086464,0.08139999993145466,0.13346666637808086,-6.513872666325858,1.842753290485081,-39.010988930474305,42.920279321676674,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2024-12-30,0.07249999791383743,0.07699999958276749,0.0689999982714653,0.07450000196695328,770861,0.0,0.0,0.08260000124573708,0.08023749999701976,0.13235416635870934,-9.806294378478395,2.9443854168002033,-39.376672299413514,40.05158186839087,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-02,0.07050000131130219,0.08250000327825546,0.07000000029802322,0.07400000095367432,1453189,0.0,0.0,0.08125000149011612,0.07913750000298023,0.13122083308796087,-8.923077419664722,2.6694063965330415,-39.69135986971503,39.57679646663768,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-03,0.07000000029802322,0.07500000298023224,0.06750000268220901,0.0689999982714653,2759704,0.0,0.0,0.07920000106096267,0.07836249992251396,0.12982916639496883,-12.878791228356315,1.0687524508238626,-39.64183696279923,35.09632822904281,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-07,0.0689999982714653,0.07150000333786011,0.06300000101327896,0.07150000333786011,1954661,0.0,0.0,0.07785000130534173,0.07797500006854534,0.1267916665102045,-8.156708877339364,-0.16030620467294665,-38.50147867386085,38.82546876534988,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-08,0.07349999994039536,0.07349999994039536,0.06800000369548798,0.06800000369548798,189221,0.0,0.0,0.07580000162124634,0.07750000022351741,0.12394166657080254,-10.290234510459515,-2.193546577249182,-37.47058405153444,35.730276343028464,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-09,0.06849999725818634,0.07349999994039536,0.05999999865889549,0.06549999862909317,1479486,0.0,0.0,0.07410000115633011,0.07690000012516976,0.12303749993443489,-11.605941151192917,-3.641090980860989,-37.498729926933834,33.66576620081062,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-10,0.06599999964237213,0.06650000065565109,0.061500001698732376,0.06599999964237213,1395520,0.0,0.0,0.07250000089406967,0.07655000016093254,0.12217916660010815,-8.965518857295942,-5.290658730696894,-37.34611039582523,34.4811490958667,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-13,0.07850000262260437,0.07900000363588333,0.05999999865889549,0.07000000029802322,7945441,0.0,0.0,0.07135000079870224,0.07648750022053719,0.12132916655391454,-1.8920819699606377,-6.716783012939293,-36.95868652773713,40.75519922498331,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-14,0.07000000029802322,0.07900000363588333,0.06599999964237213,0.06949999928474426,746469,0.0,0.0,0.07055000066757203,0.07650000024586916,0.12049166653305292,-1.4883081118245722,-7.777777201534608,-36.51013182319633,40.23652144253055,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-15,0.0729999989271164,0.0729999989271164,0.06449999660253525,0.06949999928474426,1616847,0.0,0.0,0.0697500005364418,0.07655000016093254,0.1196541665121913,-0.35842473085992466,-8.883082443102506,-36.0239577172325,40.23652144253055,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-16,0.06949999928474426,0.07450000196695328,0.06499999761581421,0.06849999725818634,1408454,0.0,0.0,0.06915000006556511,0.07648750003427267,0.11878333321462074,-0.939989597631911,-9.593070717986278,-35.607548665036106,39.082803371834295,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-17,0.06949999928474426,0.07400000095367432,0.06300000101327896,0.06849999725818634,608771,0.0,0.0,0.06859999969601631,0.07616249993443489,0.11793749984353781,-0.1457761490861578,-9.929427533141398,-35.42130362651733,39.082803371834295,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-20,0.0689999982714653,0.07400000095367432,0.061500001698732376,0.06650000065565109,1984409,0.0,0.0,0.06834999993443489,0.07583750002086162,0.11709166653454303,-2.706655860363445,-9.873084007736344,-35.2323677121045,36.64556275397732,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-21,0.06650000065565109,0.06650000065565109,0.05950000137090683,0.0625,865399,0.0,0.0,0.06744999960064887,0.07533749993890523,0.11617083325982094,-7.338768910239185,-10.46955413260688,-35.14938489731777,32.306304751430474,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-22,0.06199999898672104,0.06599999964237213,0.05950000137090683,0.06499999761581421,357048,0.0,0.0,0.06714999899268151,0.07497499994933605,0.11526249994834264,-3.2017891423968936,-10.436813553774254,-34.95282508800546,37.30323647773957,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-23,0.06599999964237213,0.06599999964237213,0.057999998331069946,0.06199999898672104,771011,0.0,0.0,0.06679999902844429,0.07459999993443489,0.11435416657477618,-7.185628909484485,-10.455765298721095,-34.76407360666307,34.054627275290926,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-24,0.06400000303983688,0.06400000303983688,0.05999999865889549,0.0625,715082,0.0,0.0,0.06644999906420708,0.07427500002086163,0.11348333327720563,-5.944317712315401,-10.535174627339936,-34.549860428024125,35.06955208104989,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-27,0.061500001698732376,0.061500001698732376,0.05849999934434891,0.05999999865889549,555723,0.0,0.0,0.0654499989002943,0.07396250003948808,0.11263333326205612,-8.326967659237512,-11.50921228277709,-34.33338258097655,32.38570974268251,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-28,0.05999999865889549,0.06949999928474426,0.05999999865889549,0.0625,1302342,0.0,0.0,0.06474999897181988,0.07371250009164214,0.11183749986812472,-3.474901942159272,-12.158726279368825,-34.08963882547302,37.533913884955666,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-29,0.06499999761581421,0.07000000029802322,0.0625,0.06400000303983688,477636,0.0,0.0,0.06419999934732915,0.07356250016018748,0.1110291665730377,-0.31152073134807906,-12.727273804548286,-33.74488665390795,40.46305563107457,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-30,0.06199999898672104,0.06849999725818634,0.06199999898672104,0.06700000166893005,982827,0.0,0.0,0.0640499997884035,0.07348750019446015,0.11017916658893227,4.6057796881689566,-12.842320641038887,-33.30181878336868,45.92453110010707,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-01-31,0.06599999964237213,0.06650000065565109,0.05350000038743019,0.060499999672174454,5095270,0.0,0.0,0.06325000002980233,0.07322500012814999,0.10928333327174186,-4.347826650327463,-13.622396832899367,-32.99527207312565,37.82777034646039,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-03,0.05849999934434891,0.06499999761581421,0.0430000014603138,0.06350000202655792,4940772,0.0,0.0,0.062950000166893,0.07293750010430813,0.10840416662395,0.873712244967041,-13.693230400180942,-32.71706948559866,42.83703642961408,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-04,0.05999999865889549,0.05999999865889549,0.05000000074505806,0.052000001072883606,3977813,0.0,0.0,0.06190000027418137,0.07240000013262034,0.10750416666269302,-15.993536603306083,-14.502762208847178,-32.65377298371712,32.145154755980855,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-05,0.050999999046325684,0.051500000059604645,0.04899999871850014,0.05050000175833702,5141675,0.0,0.0,0.06045000068843365,0.07175000021234154,0.10660000005736947,-16.45988224446858,-15.749128209708646,-32.692307529336325,31.056318518860465,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-06,0.05000000074505806,0.054499998688697815,0.04800000041723251,0.05050000175833702,1894447,0.0,0.0,0.05930000096559525,0.07102500032633544,0.10567083340138198,-14.839796060650695,-16.508270759405633,-32.78656177854412,31.056318518860465,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-07,0.05000000074505806,0.05950000137090683,0.04899999871850014,0.052000001072883606,979614,0.0,0.0,0.058250001072883605,0.07021250035613776,0.10476250008990368,-10.72961353628109,-17.03756342898623,-32.97935778939627,33.662331736140345,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-10,0.051500000059604645,0.05550000071525574,0.05050000175833702,0.051500000059604645,1177436,0.0,0.0,0.05740000121295452,0.06950000040233136,0.10387500002980232,-10.278747436713145,-17.410070675295913,-33.09265907832355,33.211683637228035,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-11,0.052000001072883606,0.057999998331069946,0.04749999940395355,0.0560000017285347,688413,0.0,0.0,0.05675000138580799,0.0688125004991889,0.10285000000149011,-1.3215852668875034,-17.529517203815445,-33.094311620620395,40.88241081663032,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-12,0.0560000017285347,0.0560000017285347,0.04899999871850014,0.05350000038743019,580080,0.0,0.0,0.05570000112056732,0.06813750052824616,0.10188750000670552,-3.949731936943847,-18.25353045130107,-33.12476945281627,38.253819349150426,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-13,0.05350000038743019,0.05550000071525574,0.05050000175833702,0.051500000059604645,1282785,0.0,0.0,0.05415000095963478,0.06748750051483512,0.10098333337033788,-4.893815056449459,-19.76291824923712,-33.16966447588229,36.24601508942165,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-14,0.051500000059604645,0.057999998331069946,0.04749999940395355,0.05350000038743019,717484,0.0,0.0,0.053450001031160356,0.06663750056177378,0.10004583342621724,0.09354416334002752,-19.78990721356431,-33.39302769573283,39.6568390716144,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-17,0.05000000074505806,0.05299999937415123,0.04500000178813934,0.05299999937415123,1036363,0.0,0.0,0.052400000765919684,0.06572500048205257,0.09913750008369486,1.1450354951555224,-20.27386781042554,-33.70318958359294,39.09374015009845,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-18,0.052000001072883606,0.05249999836087227,0.04450000077486038,0.048500001430511475,3866988,0.0,0.0,0.05205000080168247,0.06481250049546361,0.09823333338523904,-6.820363720448289,-19.69141692762559,-34.021886194892566,34.36439110395942,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-19,0.048500001430511475,0.052000001072883606,0.04100000113248825,0.04450000077486038,4539409,0.0,0.0,0.05145000070333481,0.06371250050142407,0.09731250004842877,-13.50826012335497,-19.246615187886366,-34.52793786027822,30.79785189550114,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-20,0.050999999046325684,0.050999999046325684,0.04399999976158142,0.04899999871850014,1121578,0.0,0.0,0.05130000039935112,0.06287500038743019,0.09642916669448216,-4.483434040831069,-18.40954261114106,-34.79669840284122,38.527443692253385,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-21,0.04899999871850014,0.05050000175833702,0.04500000178813934,0.04500000178813934,887806,0.0,0.0,0.05060000047087669,0.06195000037550926,0.09547083340585232,-11.067190969613685,-18.321226530806566,-35.111071972990906,34.805909632708435,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-24,0.04349999874830246,0.05050000175833702,0.04349999874830246,0.04699999839067459,823490,0.0,0.0,0.050150000303983686,0.06108750030398369,0.09458750008294979,-6.281160307508259,-17.90464488737107,-35.416941720193286,38.029155971552115,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-25,0.04749999940395355,0.050999999046325684,0.04349999874830246,0.04399999976158142,3674831,0.0,0.0,0.04895000010728836,0.060250000283122065,0.09371250004818042,-10.112360234642601,-18.75518692569898,-35.70761611082222,35.21655202074726,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-26,0.048500001430511475,0.05249999836087227,0.04349999874830246,0.05050000175833702,800916,0.0,0.0,0.048650000244379044,0.05957500031217933,0.09286666677022974,3.802675240832551,-18.33822914066659,-35.84888702899233,44.75096032949962,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-27,0.02800000086426735,0.02800000086426735,0.017500000074505806,0.01899999938905239,44650792,0.0,0.0,0.04540000017732382,0.0581875002477318,0.09180833344968657,-58.14978124484145,-21.97636952260456,-36.62067694582419,25.310357013295317,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-02-28,0.01899999938905239,0.01899999938905239,0.014999999664723873,0.01600000075995922,9810660,0.0,0.0,0.041650000214576724,0.05673750024288893,0.09074166684101025,-61.58463222682165,-26.5917602356885,-37.473597060654065,24.230741213548427,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-03,0.016499999910593033,0.019500000402331352,0.01549999974668026,0.01899999938905239,3141324,0.0,0.0,0.03825000021606684,0.055487500270828605,0.08964166689353685,-50.32679926346385,-31.065555252313327,-38.10077144512666,27.55843582201338,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-04,0.017500000074505806,0.017999999225139618,0.01600000075995922,0.017000000923871994,1931648,0.0,0.0,0.03510000016540289,0.054125000210478905,0.08853333351823191,-51.5669491630703,-35.150115420032215,-38.86483422728819,26.716040762355732,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-05,0.017000000923871994,0.019500000402331352,0.01549999974668026,0.01850000023841858,1494588,0.0,0.0,0.03250000011175871,0.05288750012405217,0.08746250018787881,-43.07692253907051,-38.54880636156527,-39.5312276570597,28.481769913101942,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-06,0.017999999225139618,0.01850000023841858,0.01549999974668026,0.01549999974668026,3027535,0.0,0.0,0.02915000021457672,0.051637500151991846,0.08636666685342789,-46.82675940794901,-43.54877728632203,-40.211308328448766,27.076614155053093,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-07,0.01549999974668026,0.01850000023841858,0.014000000432133675,0.017000000923871994,5016685,0.0,0.0,0.026350000128149986,0.05041250018402934,0.08533333350593846,-35.48386777535264,-47.73121739259095,-40.92285146633693,28.963704769029448,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-10,0.017000000923871994,0.01850000023841858,0.014999999664723873,0.016499999910593033,2830214,0.0,0.0,0.02330000028014183,0.04907500017434359,0.0843958335618178,-29.18455059137624,-52.52165013272262,-41.851394668200776,28.697124331149595,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-11,0.016499999910593033,0.016499999910593033,0.012500000186264515,0.013000000268220901,3118150,0.0,0.0,0.020200000330805778,0.0476625001989305,0.08342083360378941,-35.643564082544096,-57.61867244375265,-42.86499170542283,26.835204918982697,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-12,0.012500000186264515,0.013000000268220901,0.004999999888241291,0.00800000037997961,24514615,0.0,0.0,0.015950000192970038,0.046125000226311386,0.08242083355629196,-49.84325841258854,-65.4200539518446,-44.037207298068836,24.399676268511655,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-13,0.006500000134110451,0.02800000086426735,0.006500000134110451,0.01850000023841858,45857737,0.0,0.0,0.015900000277906657,0.04487500030081719,0.08143333360397567,16.35220072369854,-64.56824474357249,-44.89357328897765,37.274380675788855,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-14,0.017999999225139618,0.03400000184774399,0.013500000350177288,0.017500000074505806,38619525,0.0,0.0,0.016050000209361315,0.043600000371225175,0.08037916698958725,9.03426695470549,-63.18807322773813,-45.75708855396156,36.634499498056776,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-17,0.01850000023841858,0.020500000566244125,0.010499999858438969,0.012000000104308128,16049806,0.0,0.0,0.01535000028088689,0.0422375003574416,0.0792625003416712,-21.82410498552255,-63.65788659133458,-46.71187487731093,33.25329891792484,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-18,0.012500000186264515,0.023000000044703484,0.012000000104308128,0.014999999664723873,31245007,0.0,0.0,0.015150000154972077,0.0410500003490597,0.07819583361657957,-0.9901022357347985,-63.093787999641016,-47.503596482721015,36.68590721500897,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-19,0.014999999664723873,0.019999999552965164,0.009999999776482582,0.012500000186264515,29771204,0.0,0.0,0.01455000014975667,0.039737500413320956,0.07713333361316473,-14.089346683109403,-63.38471217762061,-48.482065338170784,35.06744709372285,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-20,0.010499999858438969,0.013000000268220901,0.009499999694526196,0.011500000022351742,6763762,0.0,0.0,0.014150000177323818,0.038475000439211725,0.07602083364812036,-18.727916054862337,-63.22287195375085,-49.38887329583628,34.41345004262753,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-21,0.011500000022351742,0.013000000268220901,0.009499999694526196,0.010999999940395355,12846683,0.0,0.0,0.013550000078976155,0.03718750043772161,0.07486250026461978,-18.819189104930835,-63.56302542659861,-50.32559651858634,34.0713012219322,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-24,0.010499999858438969,0.011500000022351742,0.010499999858438969,0.010499999858438969,3746885,0.0,0.0,0.012950000073760747,0.0359500004677102,0.07367500028728197,-18.918920473876767,-63.97774713412796,-51.20461441801173,33.7103612967652,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-25,0.011500000022351742,0.011500000022351742,0.009499999694526196,0.010999999940395355,3270001,0.0,0.0,0.012750000040978194,0.03466250046622008,0.07254166695444535,-13.725490940850044,-63.21673315690669,-52.21711614652113,34.458100091581144,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-26,0.010999999940395355,0.014000000432133675,0.009999999776482582,0.012000000104308128,8360182,0.0,0.0,0.013150000013411045,0.03336250039283186,0.07141666695630798,-8.74524644813755,-60.584488996405064,-53.28471375842461,36.01267933963139,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-27,0.012000000104308128,0.012000000104308128,0.004999999888241291,0.008999999612569809,12586329,0.0,0.0,0.012199999950826167,0.03191250034142286,0.07030000023078173,-26.229511075036182,-61.77046668138879,-54.605262821251635,33.44944290976029,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-28,0.00800000037997961,0.010999999940395355,0.005499999970197678,0.008999999612569809,6034911,0.0,0.0,0.011349999904632568,0.03062500033993274,0.06921666690614074,-20.70484856218891,-62.938776232981766,-55.754875655222044,33.44944290976029,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-03-31,0.00800000037997961,0.010499999858438969,0.00800000037997961,0.00800000037997961,1088432,0.0,0.0,0.010949999932199717,0.02923750029876828,0.06815000018104911,-26.940635346903502,-62.54809809215798,-57.09831222143043,32.5537041790529,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-01,0.007000000216066837,0.012799999676644802,0.007000000216066837,0.009999999776482582,5120044,0.0,0.0,0.010449999943375587,0.028187500266358256,0.06708333354132871,-4.306221716089743,-62.926829819501066,-57.98136619285251,36.23170763070257,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-02,0.008799999952316284,0.009999999776482582,0.008799999952316284,0.009999999776482582,1916589,0.0,0.0,0.010199999902397394,0.027175000216811896,0.06604166682809591,-1.9607855669469598,-62.46550203857171,-58.85173478805821,36.23170763070257,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-03,0.009999999776482582,0.009999999776482582,0.00860000029206276,0.009399999864399433,2725001,0.0,0.0,0.009989999886602163,0.026147500169463454,0.06496166683888684,-5.905906195194188,-61.79367120429716,-59.74933919981985,35.55706981258737,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-04,0.008799999952316284,0.012799999676644802,0.008200000040233135,0.008999999612569809,3262105,0.0,0.0,0.00978999985381961,0.02507250013295561,0.06390333344073346,-8.069461215993568,-60.953236406801295,-60.764957345755896,35.08800344170682,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-07,0.010499999858438969,0.010499999858438969,0.008200000040233135,0.009700000286102295,1200942,0.0,0.0,0.009709999896585941,0.02402750013861805,0.0628675000819688,-0.10298260134031802,-59.58797277882603,-61.780729140986715,36.6626783396347,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-08,0.009700000286102295,0.012000000104308128,0.009700000286102295,0.01140000019222498,3368887,0.0,0.0,0.009749999921768903,0.022912500100210308,0.06186250008953114,16.92307983277115,-57.446809038183446,-62.96221448042035,40.44140521531075,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-09,0.01140000019222498,0.01140000019222498,0.009700000286102295,0.01119999960064888,1002030,0.0,0.0,0.00966999987140298,0.021855000080540775,0.0608475000752757,15.82212771036903,-55.753832826507555,-64.08233690208553,40.13801001136179,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-10,0.01119999960064888,0.023000000044703484,0.010499999858438969,0.012500000186264515,34995787,0.0,0.0,0.01001999992877245,0.020880000083707273,0.05978500007186085,24.75050174771698,-52.011494786386116,-65.07485145335826,43.12478480527562,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-11,0.013500000350177288,0.02290000021457672,0.010999999940395355,0.01119999960064888,12460324,0.0,0.0,0.010239999927580356,0.01982250006403774,0.0587700000576054,9.374996873611947,-48.34153162063594,-66.27105658565927,40.92574733441701,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-14,0.013000000268220901,0.013000000268220901,0.00989999994635582,0.011900000274181366,1642537,0.0,0.0,0.010629999917000532,0.018795000086538494,0.05778583343296002,11.94732236215473,-43.44240559693301,-67.47472698763887,42.622379953185906,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-15,0.011900000274181366,0.012799999676644802,0.01140000019222498,0.012000000104308128,1728599,0.0,0.0,0.010829999949783087,0.01788250005338341,0.056802500140232345,10.803325576640239,-39.43799850438683,-68.51811098237644,42.874787822068726,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-16,0.012000000104308128,0.012299999594688416,0.010200000368058681,0.01140000019222498,1962527,0.0,0.0,0.010969999991357327,0.017055000038817526,0.05583916677472492,3.919783055664779,-35.67868679924137,-69.45692240068074,41.68976579519743,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-17,0.010300000198185444,0.012500000186264515,0.010300000198185444,0.011900000274181366,2724418,0.0,0.0,0.01122000003233552,0.016127500077709557,0.05490500012723108,6.060608198628487,-30.429390926848498,-70.62653667181972,43.101106388498415,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-22,0.011800000444054604,0.011800000444054604,0.01080000028014183,0.011300000362098217,2625848,0.0,0.0,0.01145000010728836,0.015285000042058527,0.05398250011882434,-1.3100414304333765,-25.089956978853124,-71.68526835842405,41.79383701547453,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-23,0.010900000110268593,0.011300000362098217,0.010400000028312206,0.01119999960064888,112647,0.0,0.0,0.011600000038743018,0.014390000072307885,0.053034166782163085,-3.4482796272256104,-19.38846434708463,-72.86654821708699,41.56754571685413,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-24,0.010999999940395355,0.011300000362098217,0.010400000028312206,0.010400000028312206,180784,0.0,0.0,0.011500000022351742,0.013550000078976155,0.05207916678239902,-9.565217320882981,-15.129151621225025,-73.98191845965633,39.71494956904473,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-25,0.010700000450015068,0.011300000362098217,0.009999999776482582,0.010599999688565731,1062659,0.0,0.0,0.011440000031143427,0.012552500027231872,0.051175833423621954,-7.3426603172284945,-8.862776288985824,-75.4718209993277,40.4297421561526,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-28,0.010599999688565731,0.019999999552965164,0.00930000003427267,0.013100000098347664,19069665,0.0,0.0,0.011500000022351742,0.012405000044964254,0.05027666676323861,13.91304411205317,-7.295445540767186,-75.32652651103243,48.62915292117976,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-29,0.012900000438094139,0.017899999395012856,0.012000000104308128,0.01489999983459711,11421365,0.0,0.0,0.011870000045746565,0.0123775000218302,0.04941750008923312,25.52653561224122,-4.100181581002285,-74.95320483739533,53.58304824186929,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-04-30,0.01489999983459711,0.017500000074505806,0.013000000268220901,0.014999999664723873,2488951,0.0,0.0,0.012179999984800816,0.012277500028721989,0.04870916674068818,23.152706760608208,-0.7941359698072162,-74.79427210470789,53.849316708866255,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-02,0.015799999237060547,0.015799999237060547,0.012799999676644802,0.012799999676644802,1190145,0.0,0.0,0.012259999942034482,0.012172499997541308,0.04809083342552185,4.4045655559824555,0.7188329801671645,-74.68852350751453,47.40632580966272,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-05,0.015699999406933784,0.017799999564886093,0.012299999594688416,0.014999999664723873,3488085,0.0,0.0,0.012619999889284372,0.012084999983198941,0.04749083344358951,18.858952427252845,4.4269748186115745,-74.55298400363152,53.40960323129761,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-06,0.016499999910593033,0.017500000074505806,0.013199999928474426,0.01679999940097332,9294930,0.0,0.0,0.013109999801963567,0.012117499974556268,0.046885000083905955,28.146450455758803,8.190631974345388,-74.15484706650177,57.667216169053965,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-07,0.01679999940097332,0.017999999225139618,0.014800000004470348,0.017999999225139618,1060230,0.0,0.0,0.013779999688267708,0.012142499932087958,0.04636833342568328,30.62409022015304,13.485688823044317,-73.8129472530012,60.273622700350955,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-08,0.017999999225139618,0.019500000402331352,0.014999999664723873,0.018200000748038292,2248184,0.0,0.0,0.01447999980300665,0.012184999953024089,0.04591583344930162,25.690614610776553,18.834631586625363,-73.46231345995655,60.70784090143723,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-09,0.018799999728798866,0.018799999728798866,0.014999999664723873,0.018799999728798866,2716168,0.0,0.0,0.015319999773055315,0.012329999939538538,0.04549750012811273,22.715404747356104,24.249796011180518,-72.89961007787353,62.04802760750632,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-12,0.01679999940097332,0.01679999940097332,0.013799999840557575,0.016300000250339508,4073631,0.0,0.0,0.01588999982923269,0.012537499936297537,0.045070833441180486,2.580241821982544,26.739779939932628,-72.1826756262239,53.812084859553195,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-13,0.016699999570846558,0.019999999552965164,0.014999999664723873,0.01940000057220459,3742415,0.0,0.0,0.016519999876618386,0.012559999944642186,0.04464083342657735,17.433418384357367,31.528662017753007,-71.86432469882055,60.76634063256622,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-14,0.019899999722838402,0.027000000700354576,0.019899999722838402,0.025100000202655792,15067945,0.0,0.0,0.017539999913424253,0.012749999947845935,0.044170833417835335,43.101484187839056,37.56862733468145,-71.13479877720006,69.77701712312567,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-15,0.025599999353289604,0.026900000870227814,0.0210999995470047,0.022700000554323196,5048699,0.0,0.0,0.018310000002384186,0.013017499959096313,0.043697500112466515,23.975972426910857,40.65680860317271,-70.20996641548716,63.19577788552923,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-16,0.022700000554323196,0.024700000882148743,0.017100000753998756,0.01940000057220459,7426317,0.0,0.0,0.018970000091940165,0.01312749998178333,0.04317166675658276,2.266739473802748,44.50580931833411,-69.59232531882344,55.45126386486113,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-19,0.01810000091791153,0.01940000057220459,0.017100000753998756,0.01759999990463257,3275223,0.0,0.0,0.019230000115931033,0.013254999974742531,0.042655833445799846,-8.47634010125718,45.077330460761175,-68.92570393312126,51.72758898627558,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-20,0.018400000408291817,0.018400000408291817,0.016899999231100082,0.017100000753998756,2708791,0.0,0.0,0.01926000025123358,0.013394999993033707,0.04215666678889344,-11.214950514325547,43.78499635125094,-68.22566627453871,50.70893640281955,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-21,0.017100000753998756,0.020600000396370888,0.017000000923871994,0.018699999898672104,5970727,0.0,0.0,0.019330000318586827,0.013587499991990626,0.04168333348352462,-3.259184736323797,42.26311190418555,-67.40303892115274,53.8414379406665,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-22,0.01899999938905239,0.0210999995470047,0.01600000075995922,0.01759999990463257,1023930,0.0,0.0,0.019270000234246253,0.013764999993145465,0.04122583350011458,-8.666322310914113,39.99273696943047,-66.61074179832602,51.42191914455483,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-23,0.016899999231100082,0.01889999955892563,0.01600000075995922,0.017799999564886093,753981,0.0,0.0,0.019170000217854977,0.013934999983757735,0.040770000180539986,-7.1465865279065675,37.56727836526027,-65.82045640900174,51.845629732462484,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-26,0.017100000753998756,0.019600000232458115,0.016100000590085983,0.017799999564886093,1482820,0.0,0.0,0.019320000149309634,0.014079999970272183,0.04033500017443051,-7.867497788181206,37.21591044105774,-65.09235178038281,51.84562973246247,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-27,0.017799999564886093,0.017999999225139618,0.014999999664723873,0.01759999990463257,3566627,0.0,0.0,0.019140000082552434,0.014294999977573752,0.039898333504485586,-8.045977906362149,33.89297035732496,-64.17143594238934,51.32642416765534,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-28,0.016499999910593033,0.016899999231100082,0.015399999916553497,0.01679999940097332,913184,0.0,0.0,0.018310000002384186,0.01448999997228384,0.03944666681345552,-8.246862923070704,26.363009229863078,-63.266858412125195,49.20380744806983,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-05-30,0.016699999570846558,0.01899999938905239,0.015599999576807022,0.01730000041425228,2639410,0.0,0.0,0.017769999988377094,0.014722499973140657,0.038965833458739024,-2.6449047520102824,20.69960958258595,-62.21689961096216,50.579443382663044,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-02,0.01730000041425228,0.01730000041425228,0.01600000075995922,0.01720000058412552,1272661,0.0,0.0,0.017549999989569187,0.01490249999333173,0.038496666797436775,-1.994298607701937,17.765475574045336,-61.288856326844424,50.28612882649127,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-03,0.016599999740719795,0.018799999728798866,0.016300000250339508,0.016300000250339508,485455,0.0,0.0,0.017420000024139883,0.015060000005178154,0.0379950001447772,-6.429390196603486,15.670650850931464,-60.36320582236318,47.61012352078898,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-04,0.016300000250339508,0.018400000408291817,0.015599999576807022,0.017400000244379044,818458,0.0,0.0,0.01744999997317791,0.015260000014677644,0.03747750017015884,-0.28653139756859985,14.3512447994354,-59.28223615397834,51.03953056351006,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-05,0.016300000250339508,0.01899999938905239,0.015599999576807022,0.01899999938905239,2874862,0.0,0.0,0.01747999992221594,0.015510000009089708,0.03693166683272769,8.695649162473007,12.701482346690543,-58.00352017866351,55.59292792356143,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-09,0.01899999938905239,0.019099999219179153,0.01640000008046627,0.017100000753998756,1407849,0.0,0.0,0.017430000007152557,0.01569500002078712,0.036407500187245506,-1.8932831498472908,11.05447584624104,-56.890750696787784,49.68380470543135,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-10,0.018400000408291817,0.018400000408291817,0.016100000590085983,0.016599999740719795,661086,0.0,0.0,0.017310000024735928,0.01582500000949949,0.035850000202966234,-4.10167696707998,9.38388634657198,-55.85774080918937,48.230919443404154,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-11,0.016200000420212746,0.016200000420212746,0.013799999840557575,0.01489999983459711,6545181,0.0,0.0,0.017020000051707028,0.015917500015348196,0.03530333354137838,-12.455935432839736,6.926339156876167,-54.912189817169555,43.56616777927809,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-12,0.01489999983459711,0.01489999983459711,0.013500000350177288,0.013500000350177288,1094568,0.0,0.0,0.016610000096261502,0.015942500019446016,0.03477000020599614,-18.72365880831149,4.186922226760522,-54.14869161635292,40.12444645271114,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-13,0.013500000350177288,0.014100000262260437,0.013500000350177288,0.014100000262260437,291860,0.0,0.0,0.016340000182390214,0.016015000035986306,0.03415833355393261,-13.70868968865648,2.0293483963385652,-53.11539419597208,42.230797298028385,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-16,0.013500000350177288,0.015200000256299973,0.010300000198185444,0.015200000256299973,6221677,0.0,0.0,0.016130000166594983,0.01609750003553927,0.033539166868043445,-5.765653445069566,0.2018955178379283,-52.003876247512935,45.98260835302474,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-17,0.011800000444054604,0.01489999983459711,0.011800000444054604,0.012799999676644802,2072283,0.0,0.0,0.01569000007584691,0.016117500024847686,0.03293750019123157,-18.41937785361109,-2.6523961429608565,-51.066413870903304,39.89476044654719,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-18,0.013000000268220901,0.01489999983459711,0.011800000444054604,0.01489999983459711,1302259,0.0,0.0,0.015550000034272671,0.016205000015906988,0.03232416685204953,-4.180065583555885,-4.041962239996067,-49.86723063867769,46.56154947735555,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-19,0.014000000432133675,0.014800000004470348,0.012900000438094139,0.013700000010430813,886214,0.0,0.0,0.015180000010877848,0.016250000009313224,0.031750833491484325,-9.749670615194209,-6.584615371213147,-48.82024116415234,43.58644406929372,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-23,0.013700000010430813,0.013700000010430813,0.012400000356137753,0.012400000356137753,65080,0.0,0.0,0.014520000107586384,0.016277500009164215,0.031170833475577333,-14.600549144217828,-10.797111967982554,-47.77970880400807,40.562677342895455,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-24,0.013700000010430813,0.013700000010430813,0.012400000356137753,0.012400000356137753,421389,0.0,0.0,0.014050000067800283,0.016307500028051435,0.030595000134781003,-11.743770133097657,-13.843323356540866,-46.698807137729844,40.562677342895455,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-25,0.012400000356137753,0.013199999928474426,0.004000000189989805,0.007899999618530273,18233425,0.0,0.0,0.013180000055581332,0.016245000017806887,0.030015000126635036,-40.060701174391404,-18.86734354488069,-45.87706163828658,31.726606621294877,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
2025-06-26,0.006000000052154064,0.008999999612569809,0.004800000227987766,0.006599999964237213,29694813,0.0,0.0,0.012350000068545341,0.016145000024698673,0.029424166788036624,-46.55870503963,-23.505729020425697,-45.13013693470851,29.71291411831379,,,0.0,0.0,-1.8612801,0.798,0.18857142,0.04125,Scandion Oncology A/S,Healthcare,"Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark."
